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  2 Abstract 
Background: Obesity in Qatar is amongst the highest globally and constitutes a 
serious health risk. Obese individuals are at greater risk of vascular disease 
compared to the lean, especially in the insulin resistant state. The impact of obesity 
on endothelial vasomotor function is also adipose tissue depot-dependent, with the 
visceral environment being more pathogenic. It is, however, unclear how severe the 
impact of vascular dysfunction is in a relatively young and obese population. 
Further, it is becoming apparent that obesity-associated vascular dysfunction is 
heterogeneous. Recent research has focussed on different groups of obese subjects in 
order to elucidate the mediators of the differential cardiometabolic risk. In 
pathological obese (PO)  subjects, sub-cutaneous adipocyte dysfunction and 
inflammation have been reported along with adipocyte hypertrophy. 
This led to the following hypotheses: 
1.  The enlarged adipocytes are more susceptible to hypoxia due to decreased 
capillary density of the depot and changes in vascular tone. Hypoxia leads to 
cell necrosis and the formation of immunological foci.  
2.  The more hypoxic and inflamed fat depot secretes less adiponectin, which 
then may determine the increased systemic insulin resistance and 
dyslipidaemia seen in the PO.  
Specifically differences between metabolically healthy but obese (MHO) and 
pathologically obese (PO) in relation to capillary density and vascular function was 
determined. 
To facilitate the overall objectives, in this study: 
1.  A cohort of MHO and PO subjects were identified.  
2.  Vascular differences in the adipose tissue of PO versus MHO by functional 
studies (myography) and histological assessment of vascular density were 
carried out, and, 
3.  Mechanisms that underlie these differences were investigated.  
Methods: Patients were recruited from the local hospital and blood and adipose 
tissue (Omental, OM; Subcutaneous, SC) samples collected. Fasting plasma glucose 
and insulin were assayed to determine insulin resistance status. Vascular function 
  3 was assessed by wire myography. Cumulative concentration-response curves were 
generated for various vasoconstrictors (e.g. noradrenaline, potassium chloride), and 
vasodilators (e.g. acetylcholine, Sodium nitroprusside (SNP), and prostaglandin E2). 
Relaxation to acetylcholine was recorded in the absence or presence of Nω-Nitro-L-
arginine methyl ester (L-NAME), indomethacin, diclofenac, BaCl2, 
apamin+charybdotoxin, and arginine.  
mRNA expression of hypertension associated genes in stromal vascular fractions 
(SVFs) of both depots was assessed  by real time RT-PCR. Paraffin-embedded 
tissues were used for histological studies.  
Results:  OM arterioles were less sensitive to noradrenaline-mediated 
vasoconstriction compared with SC (log EC50 -5.9±0.2 vs. -6.5±0.1, p<0.05).  
Vasorelaxation to acetylcholine was attenuated in OM vessels compared with SC 
vessels (p<0.01). In contrast, relaxation to SNP was greater in OM compared with 
SC vessels (p<0.01). Acetylcholine curves for insulin-sensitive patients were less 
attenuated compared with insulin-resistant patients. L-NAME, apamin, 
charybdotoxin, and BaCl2 caused right-ward shifts of the acetylcholine curves, while 
indomethacin, diclofenac and arginine produced the reverse.  
In the whole group, COX2 mRNA, but not eNOS and COX1, were up regulated in 
OM compared with SC SVFs.  However, when analyzed separately, in the OM 
compared to SC SVFs, of the MHO several genes were unregulated (AGT, ARG2, 
CLIC5, EPHX2, ITPR1 and PRKG1), while in the PO only two were significantly 
different between the depots (CLIC5 and PDE3B). 
Conclusions: Hyperinsulinaemia in adipose tissue microvessels was associated with 
і) vasocontractile insensitivity to noradrenaline and іі) to changes in NO-mediated 
vasodilation, at least partially mediated through components of the COX2 pathway. 
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  16 1.0 INTRODUCTION 
1.1 Obesity: 
Obesity is defined as an expansion and excessive accumulation of adipose tissue. It 
is often associated with changes in the structure and function of the adipose organ, 
as well as its distribution and the secretion of adipose derived factors, adipokines 
(1).  
Obesity is also associated with susceptibility to  certain complications such as, 
hyperglycemia, hyperlipidemia, chronic inflammation, insulin resistance and 
endothelial dysfunction, which contribute to various metabolic diseases  and 
pathologies including type 2 diabetes, cardiovascular disease (CVD)  and 
hypertension (2).   
1.2 Obesity in Qatar 
Over the last century there has been socioeconomic development in many countries, 
especially in those  of the Co-operation Council for the Arab States of the Gulf 
(GCC). The discovery  of oil in this region has resulted in a move away  from 
traditional to a modern way of life in diet and life style habits which have led to an 
increase in the prevalence of obesity amongst the population. These changes have 
contributed to the increases in diseases such as, obesity, cardiovascular diseases, 
hypertension, diabetes and cancer (3). Qatar is a rapidly developing country that has 
seen a substantial increase in the prevalence of obesity in its population. The 
proportion of adult Qataris that were overweight and obese in 2005 was 34.6% for 
males and 45.3% for females (4), which puts Qatar sixth in the world for female 
obesity ranking according to WHO (2010). Globally more than 1.7 billion adults are 
overweight, and 312 million are obese. About 18 million people die every year from 
cardiovascular disease, diabetes and hypertension, major factors that are propelled 
by the increasing prevalence of overweight and obesity. When joined by 
underweight, malnutrition and infectious diseases they are the major  problems 
threatening the world (5).   
  17 1.3 Adipose tissue: 
The adipose tissue is composed of adipocytes and other cells within an endocrine, 
paracrine and autocrine organ secreting a host of factors referred to as adipokines 
which regulate many central and  peripheral processes such as appetite, energy 
metabolism, glucose homeostasis, blood pressure, lipid metabolism, inflammation, 
angiogenesis and reproductive function (4, 6). Many of these adipokines are also 
known to regulate vascular tone. The vasoactive adipokines that have been described 
include: adiponectin, omentin and visfatin as vasorelaxants, while angiotensin II and 
resistin  appear to act mainly as vasoconstrictors (7). Recently an unidentified 
adipocyte-derived relaxing factor (ADRF) was also  shown to relax arteries (8). 
Leptin, tumour necrosis factor (TNF-α), interleukin-6 (IL-6) and apelin are reported 
to have both vasorelaxant and constricting properties (8). A failure of the regulation 
of the synthesis of these vasoactive and proinflammatory adipokines may underlie 
the compromised vascular reactivity in obesity and obesity-related disorders (2).   
1.3.1 Adipose tissue Composition: 
The adipose tissue is heterogeneous  and  made up of predominantly  adipocytes 
(50%), stromal preadipocytes, progenitor cells, macrophages, fibroblasts, endothelial 
cells, vascular smooth muscle cells (as part of the blood vessels), neurons, as well as 
a host of different immune cells (9,10) as shown in figure 1. The tissue is located 
around blood vessels (perivascular), as well as around internal organs (visceral or 
omental)  and  in the subcutaneous  compartments.  The subcutaneous depot is the 
largest of the adipose tissue organs. Histologically and functionally adipose tissue 
consists of at least two distinct types; white and brown (1). In humans the white 
adipose tissue (WAT) constitutes the major type of this tissue and makes up most of 
the total body fat mass. Functionally WAT acts as an insulator, stores excess energy 
as triacylglycerol mediates glucose homeostasis and serves as an important 
endocrine/immune organ which secretes adipokines, that include inflammatory 
cytokines, acute phase proteins and complement-like factors (4, 11). In adult humans 
metabolically active brown depots are found in cervical, supraclavicular, axillary 
  18 and paraventral body’s regions, which can be induced in response to cold and SNS 
activation (10, 12). 
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Figure 1: Adipose tissue composition. Adipose tissue as a heterogeneous mixture 
of cellular structures (adipocytes, precursor cells, macrophages, fibroblasts and 
endothelial cells) and tissue structures (small blood vessels and nerve tissue). 
Vascular cells include both endothelial cells & vascular smooth muscle cells present 
within the major blood vessels (Adapted from13). 
 
 
 
   
  20 Another type of adipose tissue is the brown adipose tissue  (BAT)  which  is 
specialized in heat production and lipid oxidation; it consists of smaller number of 
fat cells, with richer vascular supplies and more abundant mitochondrial 
chromogens, responsible for the brown colour (14). BAT also responds more rapidly 
to sympathetic nervous system (SNS) stimulation that elicits heat, rather than ATP 
production (14).  
Major locations for WAT are in the intraabdominal regions, around the omentum 
and perirenal areas and subcutaneous in the buttocks, thighs and abdomen. 
Adipocytes constitute about 50% of WAT, macrophages about 10% and the rest are 
preadipocytes, endothelial and epithelial cells. Both adipocytes and non-adipocyte 
cells secrete adipokines. Adipocytes mainly produce adiponectin, and to a lesser 
extent leptin. Cytokines such as MCP-1and IL-6 are predominantly secreted by the 
hypertrophied adipocytes or they along with many of the other inflammatory signals 
are produced by the non-adipocyte cells of the stromal vascular fraction (SVF). In 
obesity, macrophages infiltrate into WAT, and the number of these macrophages 
directly correlates to adipocyte size (15). More recently other, perhaps intermediate, 
types of adipose tissue, in addition to WAT and BAT, have also been described, 
such as ‘beige’ adipose tissue (16, 17). Data suggests that the two types of brown 
adipocytes have different developmental origins; classical brown adipocytes arise 
from precursors in the dermomyotome (15), while the ‘beige’ cells seem to originate 
from endothelial and perivascular cells within WAT depots (16).  Brown fat is 
characterized by  high mitochondrial content and elevated expression of 
mitochondrial uncoupling protein 1(UCP1) which functionally uncouples respiration 
and dissipates chemical energy as heat. Recent data has shown that the adult humans 
contain significant deposits of UCP1-positive brown fat in the supraclavicular and 
neck region which can be detected by positron emission tomography (PET) (17). 
Some WAT also contain these ‘beige’ cells that resemble white fat cells in having 
extremely low basal expression of UCP1, but, after prolonged stimulation by cold or 
pathways that elevate intracellular cyclic AMP, like classical brown fat, they can 
express high levels of UCP1 and take on a multilocular appearance (18).  The 
physiological significance of the ‘beige’ fat is under investigation. 
  21 1.3.2 Adipokines 
Adipose tissue is not only a storage organ, but now known to play a key role in the 
integration of systemic metabolic functions, mediated in part by its ability to secrete 
adipokines (19). These include leptin, adiponectin, TNF-α, resistin, IL-6, omentin, 
visfatin and apelin. The secretory status of an adipose tissue depot can be modified 
following the onset of obesity by changes in the cellular composition of the tissue, 
including alterations in the number, phenotype and localization of immune, vascular 
and structural cells. Also, the expression of adipokines can vary depending on the 
site of an adipose tissue depot and the two most abundant depots are visceral and 
subcutaneous adipose tissues, which produce unique profiles of adipokines (20, 21). 
The roles of some of the adipokines with known vascular effects are discussed in the 
following sections.   
1.3.2.1  Adiponectin is an abundant, adipocyte-derived plasma protein with anti-
inflammatory, insulin sensitizing, and antiatherogenic properties. It comprises 247-
amino acid and plays an increasingly important role in energy homeostasis and 
insulin sensitivity, in contrast to  many of the other  known  adipokines (22). 
Adiponectin levels in the plasma and adipose tissue are decreased in obese compared 
with the lean (23). This may at least partly be due to adiponectin production in 
adipocytes being inhibited by pro-inflammatory factors, like TNF-α and IL-6, as 
well as by hypoxia and oxidative stress  (13).  On the other hand, adiponectin 
secretion is stimulated in adipocytes by the activation of PPARγ, a nuclear receptor, 
and PPARγ agonists promote adipocyte differentiation, and also by weight loss.  So 
adiponectin mRNA is reduced in adipose tissue from obese and diabetic humans 
probably as a consequence of inflammation in the adipose tissue, but restored to 
normal levels after weight loss or hypoglycaemic therapy.  Circulating adiponectin 
levels correlate more with hyperinsulinemia and insulin resistance than obesity or 
body fat (24).  It is however not clear if adiponectin plays a causative role or is just a 
marker of insulin resistance. Also the mechanisms by which adiponectin may cause 
insulin resistance are  not fully elucidated (32). Adiponectin inhibits TNF-α 
production and other inflammatory pathways in adipocytes and macrophages, and 
plasma levels have been correlated with endothelium-dependent vasorelaxation in 
  22 humans (25). Other studies have shown an increase in NO production as well as NO 
and potassium channel-mediated  vasorelaxation in rats by adiponectin (26). NO 
release from the endothelium may be stimulated by adiponectin binding to either the 
adiponectin type 2 receptor or T-cadherin on the endothelial surface (27). Increased 
NO production leads to inhibition of platelet aggregation, leucocyte adhesion to 
endothelial cells (5) and vascular smooth muscle cell proliferation. Moreover, 
adiponectin reduces oxidative stress by decreasing ROS production (although 
mechanism  is  unknown) in endothelial cells (5). All these effects protect the 
vascular system against endothelial dysfunction (2).  The  metabolic  effect of 
adiponectin on insulin sensitivity appears to be mediated by AMP-activated protein 
kinase (AMPK) activation  in skeletal muscle and  liver.  In skeletal muscle cells, 
adiponectin increased  intracellular Ca
2+  concentration  and the activities of 
calcium/calmodulin-dependent protein kinase kinase (CaMKK), AMPK and sirtuin 
1 (SIRT1), resulting in enhanced expression and activity of PPARγ co-activator 1α 
(PPARγC1α; PGC1α) (13). As AMPK activation leads to an increase in fatty acid 
oxidation and glucose uptake in muscle tissue, and inhibition of gluconeogenesis in 
the liver, this pathway is associated with insulin  sensitivity.  Also  disruption  of 
adiponectin receptor 1 expression, especially in muscle cells, has been shown to 
prevent these adiponectin-mediated changes and lead to insulin resistance (13). 
1.3.2.2 Leptin  is a 167-amino acid peptide hormone secreted by adipocytes in 
proportion to adipose tissue mass and circulates bound to a soluble form of its 
receptor, though evidence for this is poor. It is a signaling molecule relating the 
long-term nutritional and fat mass status to the brain (hypothalamus) (28). It exerts 
its effects through binding to the leptin receptor (Ob-R), a member of the cytokine 
family of transmembrane receptors (29). In monocytes leptin increases TNF-α and 
IL-6 production and stimulates the production of CC-chemokine  ligands (CCL3, 
CCL4 and CCL5) by macrophages (13). Also, leptin stimulates the production of 
ROS and promotes cell proliferation and migratory responses. Leptin levels in the 
serum and adipose tissues are increased in response to pro-inflammatory stimuli, 
such as TNF-α and lipopolysaccharide (LPs) (13). Under normal conditions leptin 
contributes to blood pressure homeostasis by both its vasorelaxing and 
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activation (30).  Various mechanisms may  be responsible for leptin-induced 
vasorelaxation, some of them being endothelium-dependent through the release of 
NO, or by other mechanisms (31).  The involvement of the endothelium-derived 
hyperpolarizing factor (EDHF) in leptin-induced vasorelaxation remains debatable 
(32). In obesity, endothelium-dependent vasorelaxation is likely to become less 
effective, if sustained hyperleptinemia, and thus leptin resistance, leads to 
endothelial dysfunction (29).  While the basis of leptin resistance in humans is 
unclear and may involve multiple mechanisms, one of them may be the induction of 
the suppressor of cytokine signaling-3 that blocks the intracellular pathway of leptin 
(33). Another mechanism might be defects in transfer of leptin across the blood-
brain barrier that may lead to central leptin resistance (32). Leptin production is 
augmented in large adipocytes, stimulated by insulin and affected by estrogens, 
FFAs and growth hormone, but not directly influenced by food uptake itself (34).   
1.3.2.3 Resistin is a recently discovered (in 2001) adipocyte-secreted polypeptide 
that has been implicated in the development of insulin resistance and is a member of 
a family of tissue-specific signaling molecules, called resistin-like molecules (35) 
The resistin mRNA encodes a 114-amino acid polypeptide with a 20-amino acid 
signal sequence which is secreted as a disulfide-linked dimmer (32). Resistin mRNA 
and protein expression were found to be similar in adipose tissues from both the 
abdominal subcutaneous and omental depots. However expression in abdominal 
depots was increased compared with thigh fat. This suggests a potential link between 
central obesity and increased risk of diabetes (36). Resistin may not be a major 
adipokine in humans.  Recent evidence suggests that it may come from circulating 
monocytes and macrophages (25). In human mononuclear cells, transcription of the 
resistin gene (RETN) is enhanced by proinflammatory cytokines, such as IL-1, IL-6 
and TNFα,  while  in  white  adipose  tissue  it  is  inhibited  by  the  PPARγ  agonist 
rosiglitazone, suggesting that the anti-inflammatory effect of rosiglitazone is 
mediated in part by the attenuation of RETN transcription (13). On the vascular 
endothelial cells, resistin directly counters the anti-inflammatory effects of 
adiponectin by promoting the expression of the pro-inflammatory adhesion 
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molecule 1 (ICAM1) and pentraxin 3 in these cells, thereby enhancing leukocyte 
adhesion (37). Although resistin does not directly affect the contractility of isolated 
blood vessels (38), coronary blood flow, mean arterial pressure or heart rate (39), it 
has been associated with endothelial dysfunction in coronary artery disease (40). 
Both TNF-α and IL-6 which are increased in obesity enhance resistin expression 
(41).  
1.3.2.4 TNF-α is a proinflammatory cytokine mainly produced by monocytes and 
macrophages and has a central role in inflammatory and autoimmune diseases and 
has been implicated in the pathogenesis of insulin resistance. It is expressed as a 26-
KDa cell surface transmembrane protein that undergoes cleavage to produce a 17-
kDa soluble, biologically active form (42). Adipose tissue TNF-α mRNA correlates 
with the body mass index, percentage of the body fat, and hyperinsulinemia, and 
decreased  by  weight loss (43).  In  muscle and adipose tissues,  TNF  attenuates 
insulin-stimulated tyrosine phosphorylation of the insulin receptor and insulin 
receptor substrate 1 (IRs1), thus promoting insulin resistance  (13). These  data 
suggest that TNF functions as a pro-inflammatory cytokine that has a crucial role in 
obesity related insulin resistance (13). Potential mechanisms by which adipose tissue 
TNF-α increases insulin resistance includes increased release of FFA by adipocytes, 
reduction in adiponectin synthesis and impairment of insulin signaling (44). TNFα 
acts  as  potent  inhibitor  of  adipogenesis,  possibly  through  inhibition  of  PPARγ-
dependent phenomena, as presented by the fact that thiazolidinediones prevent 
TNFα-induced anti-adipogenesis (45). TNF-α  is  a  potent,  time-dependent 
vasoconstrictor (46) and vasodilator (47). It is unclear what underlies the differential 
regulation of arterial contractility by TNF-α. (48). TNF-α is produced in the direct 
vicinity of the vascular endothelium and vasoregulation can occur through both 
endothelium-dependent and endothelium-independent mechanisms. Some studies 
have suggested that TNF-α  promotes  vasorelaxation  by  an  increase  of  NO  and 
prostaglandin production (47). On the other hand TNF-α  is  able  to  induce 
vasoconstriction by increasing endothelin-1 and angiotensinogen levels (49). In 
addition it impairs endothelium-dependent vasorelaxation in various vascular beds 
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such as ROS (46). Much of the evidence of TNF from adipose tissue is based on 
mouse studies.    
1.3.2.5 IL-6 is a proinflammatory cytokine associated with insulin resistance, and 
secreted by many cell types, including fibroblasts, immune cells, endothelial cells, 
skeletal muscle and adipose tissue, with visceral depots releasing more IL-6 
compared with subcutaneous depots (50). It circulates as a variably glycosylated 22- 
to 27-kDa protein. Plasma IL-6 levels positively correlate with human obesity and 
insulin resistance (51). This is consistence with the observation of an increase in IL-
6 at the mRNA, protein levels, and by its release in vivo by WAT in obesity (60,52). 
Elevated levels of IL-6 predict the development of type 2 diabetes (53). Weight loss 
significantly decreases IL-  6 levels in both adipose tissue and serum (54). IL-6 
exerts its adverse effects, at least partly, by decreasing adiponectin secretion (55). 
IL-6 also inhibits differentiation and lipid accumulation of fibroblasts and affects the 
main adipogenic transcription factor C/EBPα, whereas earlier activation of C/EBPδ, 
C/EBPβ and PPARγ remain intact (56). A sustained increase in IL-6 plasma levels is 
associated with high blood pressure (57). IL-6 relaxes skeletal muscle resistance 
vessels (58). The vasorelaxing effect is likely regulated by an endothelium-
independent pathway involving an increase in prostacyclin in vascular smooth 
muscle cells. IL-6 has been shown to be a predictor of future myocardial infarction 
and induces hepatic CRP production, which is now identified to be an independent 
major risk factor for cardiovascular complications (48). Certain studies have 
suggested that IL-6 is an indirect marker of vascular dysfunction, whereas others 
have suggested a more active role in vascular dysfunction (59).  
1.3.2.6 Omentin, is adipose tissue-derived cytokine consisting of 313 amino acids 
and the expression is mainly in visceral rather than in subcutaneous adipose tissue 
(60). Secretion of omentin-1 is preferentially expressed by omental stromal vascular 
fraction cells, but not by adipocytes (61). Omentin consists of two isoforms 
(codified by two genes 1 and 2) in which omentin-1 appears to be the major isoform 
in human plasma (62) and is higher in women compared with men (62). Omentin-1 
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increased phosphorylation of AKT/PKB (63). In isolated rat aorta and mesenteric, 
omentin inhibited noradrenaline- induced concentration dependent contractions, and 
directly induced an endothelium-dependent vasorelaxation which is mediated by NO 
(60). Omentin is also  capable of inducing vasorelaxation in  an endothelium-
independent way (60). Omentin-1 plasma levels and adipose tissue gene expression 
are decreased in obesity  and correlates negatively with BMI,  leptin,  and  insulin 
resistance, (62) and more so when overweight is combined with type 2 diabetes (64). 
Plasma omentin-1 correlates positively with plasma adiponectin and high-density 
lipoprotein (HDL) levels. (62). Circulating omentin-1 concentrations increases after 
weight loss-induced improvement of insulin sensitivity (65). Omentin-1 might act as 
an anti-inflammatory adipokine by attenuating C-reactive protein (CRP) and TNF-α 
induced NF-kB activation in human endothelial cells (66). 
1.3.2.7 Visfatin is a 52 kDa newly identified adipokine, which is released from 
perivascular and visceral adipose tissue that has an insulin-mimetic effect (67). 
Some studies show an increase in visfatin levels in obesity and a positive correlation 
with BMI and percentage of body fat, but not with abdominal circumference or 
visceral fat estimated on the basis of computed tomography (68).  Visfatin has 
multiple functions in the vasculature including; stimulation of growth of vascular 
smooth muscle cells (69) and endothelial angiogenesis via upregulating VEGF and 
matrix metalloproteinases (67). Visfatin also appears to mediate vascular endothelial 
inflammation by enhancing the expression of adhesion molecules (VCAM-1 and 
ICAM-1)  through  oxidative stress  dependent NF-kB activation.  It may mediate 
inflammatory responses in monocytes by induction of pro-inflammatory cytokines 
IL-1B, IL-6 and TNF-α. Visfatin with higher concentrations augment the expression 
of anti-inflammatory cytokines  such as,  IL-10  (70).  Visfatin  Plasma levels are 
negatively correlated with vascular endothelial function (71). Visfatin can directly 
affect vascular contractility and it has been shown in rat isolated aorta to induce 
endothelium-dependent vasorelaxation via  NO production.  It is also  an  effective 
dilator of resistance vessels such as mesenteric arteries of rats (72).  
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Adipokines  Sources  Functions 
Adiponectin  Adipocytes  Anti-inflammatory, insulin sensitizing, and 
antiatherogenic properties.                                   
NO-dependent vasorelaxation mediated by 
opening of Kv channels. 
Leptin  Adipocytes  Food intake and proinflammatory 
mediator. Vasorelaxation (EC dependent 
and EC independent) and vasoconstriction 
due to sympathetic nervous system 
activation. 
Resistin  Adipocytes  Proinflammatory mediator.                                                   
No direct effect on contractility of blood 
vessels.  
 
TNF-α  Monocytes and 
macrophages 
Proinflammatory cytokine.  
Vasorelaxation (EC dependent and EC-
independent), and impairs EC dependent 
vasorelaxation by decreased NO or 
increased ROS production.  
Triggers ET-1- and Ang-induced 
vasoconstriction.  
IL-6  Fibroblasts, immune 
cells, EC, skeletal 
muscle and visceral 
AT more compared 
with SAT  
Proinflammatory cytokine.                                                  
EC-independent vasorelaxation. 
Reduces vasorelaxing effect of PVAT by 
increased ROS production. 
Impairs endothelial function by increased 
ROS and decreased NO production. 
Omentin  OM SVF, but not by 
adipocytes  
Vasorelaxation (EC dependent and EC 
independent).  
Visfatin  Perivascular and 
visceral AT  
NO dependent vasorelaxation. 
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The adipose tissue is distributed in numerous discrete anatomical depots (73) and the 
size of fat stored in the depots is highly variable, ranging from 5% to 60% of total 
body weight. Approximately 85% of total adipose tissue mass, either in lean or 
obese humans, is in the subcutaneous (SC) depots, including the abdominal, gluteal, 
mammary and femoral, while the remaining 15% constitutes intra-abdominal fat, 
including both retroperitoneal adipose and visceral depots,  which encompass 
mesenteric and omental adipose depots (OM) (74). There are other smaller adipose 
depots such as epicardial and intermuscular which may serve specialized functions 
related to their neighboring tissues (75,76). 
The SC & OM depots, which are of particular interest in the current study, show 
functional differences in the expression of genes, especially those regulating 
inflammation and vascular function, presence of complement factors and fatty acid 
binding protein, which are all expressed at higher levels in OM than in SC fat. 
Expansion of these depots may happen through adipocyte hypertrophy and/or 
hyperplasia. The accumulation of excess  fat in the visceral compartment, while 
subcutaneous fat mass remain normal, carries the greater metabolic risk (28,77).   
1.3.3.1 Subcutaneous (SC) depots:  
Adipose tissue is deposited peripherally in subcutaneous depots, such as mammary 
and gluteofemoral regions. SC contains higher numbers of preadipocytes (78) and 
appears less metabolically active, secretes more leptin and less free fatty acids (79) 
than omental depot. Thus, excessive accumulation of subcutaneous adipose tissue is 
more likely to be associated with hyperleptinemia that may lead to central leptin 
resistance and greater susceptibility to further weight gain (79,80). Thus, the depot 
specific differences in adipose tissue secretory function  are dependent on the 
anatomical location of this tissue (81). Recently it was shown that SC adipose tissue 
has a higher capacity to expand its capillary network than visceral tissue (82). But 
with increasing fat accumulation, this capacity decreases, and the decrease in SC 
tissue functional angiogenesis correlates with insulin resistance and suggests that 
impaired SC vascularization capacity may contribute to metabolic diseases (82). The 
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node in the development of subsequent ectopic fat deposition in visceral depots, the 
liver and other cell types (83).  
1.3.3.2 Visceral adipose tissues (VAT): Intra-abdominal fat depots are associated 
with internal organs, and both intra and retroperitoneal depots represent 10–20% of 
total body fat in men and 5–10% in women. Intraperitoneal VAT which are 
associated with digestive organs, include the omental (OM) (hangs off the stomach), 
the mesenteric (associated with the intestine), and epiploic (along the colon) (75). 
VAT is also deposited internally in the thoracic compartments, and the epicardial 
region.  
1.3.3.2.1 Omental (OM) depots;  
The number of stromal cells (nonadipocytes) per gram of AT is greater in OM than 
SC (84) and OM secrete more of the proinflammatory cytokines, such as IL-6, 
visfatin and MCP-1, which may be responsible for the insulin resistance (85,86). 
OM depot is more heavily implicated in metabolic syndrome and more extensively 
infiltrated with immune-inflammatory cells, such as macrophages and T-
lymphocytes, than the subcutaneous depot.  
1.3.4 Obesity and Adipose tissue dysfunction: 
Obesity is an enlargement of adipose tissue, which probably has a strong genetic 
predisposition that possibly regulates both excess energy intake and/or energy 
expenditure. AT dysfunction is characterized by mainly visceral (ectopic) fat 
accumulation, (87) changes in the intracellular matrix and cellular composition of 
adipose tissue (88), increased number of immune cells infiltration (89), enlarged 
adipocytes (87), increased autophagy (90), apoptosis (91), and changes in AT 
mRNA and protein expression patterns (87). Thus, with the development of AT 
dysfunction, adipokine secretion is significantly altered toward a proinflammatory, 
atherogenic and diabetogenic pattern (92). These changes link impaired adipose 
tissue function to insulin resistance and cardiovascular disease (87, 92). There are 
two possible mechanisms, adipose tissue hyperplasia and hypertrophy, that can lead 
to increased adipose tissue size, which are influenced by diet and genetics, as well as 
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in the early stages of adipose tissue development (92,93). Hypertrophy (increase in 
adipocyte volume), on the other hand, occurs prior to hyperplasia to meet the need 
for additional fat storage capacity in the progression of obesity (94,95,96). The latter 
is  characterized by the presence of large, lipid-laden  adipocytes that  plays an 
important role in obesity-related cardiovascular and metabolic disorders. Thus, 
increased triglyceride storage was shown to be a major determinant of obesity 
development (87). The number of adipocytes appears to be set during childhood and 
adolescence, which suggests hypertrophy of adipocytes, is the major mechanism for 
adipose tissue expansion in obesity (93).  
When adipocytes  hypertrophy,  local adipose tissue hypoxia may occur due to 
hypoperfusion, and as a result hypoxia-inducible transcription factors are expressed 
triggering the expression of angiogenic factors (VEGF, hepatocyte growth factor, 
PAI-1).  These  inhibit  adiponectin gene transcription illustrated by decreased 
adiponectin promoter and peroxisome proliferator activated receptor gamma (PPAR- 
γ)  activity,  by  reduced  adiponectin  mRNA  stability  and  finally  by  a  decline  in 
adiponectin expression (97). Various unsaturated fatty acids and their metabolites 
have been shown to bind PPAR-γ and its activation results in adipocyte hyperplasia 
with a concomitant shift of TG from circulating lipoproteins and muscle tissue into 
adipocytes as shown in animal  models (98). These changes lead indirectly to 
improved endothelial function and in decreased plasma levels of insulin, FFAs, and 
cytokines. 
 PPAR-γ  and  sterol  regulatory  element  binding  proteins  (SREBP)  are  two 
transcription factors involved in the development and metabolism of adipocytes 
(99).  PPAR-γ  is  expressed  at  high  levels  in  adipose  tissue  and  activates  genes 
involved in adipocyte differentiation and fatty acid trapping such as fatty acid 
transport protein, lipoprotein lipase (LPL), fatty acid binding protein, adiponectin (as 
discussed above) and acyl-CoA synthase (100). SREBP-1c is the main isoform and 
highly expressed in most tissues including adipose tissue. Once it is activated by 
insulin it activates a cascade of genes required for endogenous lipogenesis and 
preadipocyte differentiation  (101).  The consequence of inflammation-induced 
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alteration in adipogenesis (102).  Adipogenesis is the process of  preadipocyte 
differentiation into lipid-laden and insulin responsive adipocytes. This occurs 
through several stages involving a cascade of transcription factors, including PPAR-
γ as well as enhancer binding proteins (C/EBPs), which are crucial determinants of 
adipocyte fate (103). Thus it could be envisaged that inflammation induces secretory 
changes in the tissue as a consequence of the changes in cellular make up. 
1.3.4.1 Obesity and Inflammation: 
Overall obesity may be considered a chronic, low grade inflammatory condition, 
with the cellularity and the secretions of adipose tissue reflecting these changes. 
Over-nutrition leads to adipocyte hypertrophy, followed by cell death that may act as 
a stimulus for immune cell infiltration into the tissue. An inflammatory process is 
simultaneously activated by increased adipose tissue mass in metabolically active 
sites, such as WAT, liver and immune cells.  Monocyte infiltration and 
differentiation in particular has been shown to correlate with adipocyte hypertrophy, 
as well as body mass. Monocytes move by diapedesis from the blood to adipose 
tissue and differentiate into macrophages in the obese adipose tissue which switch 
their phenotype from one of a non-inflammatory resident macrophage to that of a 
lipid glutted foam cell, expressing dendritic cell markers, such as CD11c (4).   M1-
Macrophages, the ones with the proinflammatory phenotype, are more prevalent in 
adipose  tissue  and  predominant  in  obesity,  secreting  TNFα  and  IL-6 thereby 
enhancing inflammation. TNF-α  activates  human  adipocytes  further  to  induce 
lipolysis and enhance the expression of various genes such as; ICAM-1, IL-6, MCP-
1. The secretions from these macrophages (IL-6 and TNFα) along with those from 
the hypertrophied adipocyte (MCP-1 and leptin) regulate the pathological changes of 
obesity, such as insulin resistance and endothelial dysfunction (32).  
  
1.4 Obesity and Insulin resistance: 
Insulin resistance is known as a failure of target organs to respond normally to the 
action of insulin. It manifests as suppression of hepatic glucose output and impaired 
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increased insulin requirements. Obesity is a well-defined risk factor for the 
development of insulin resistance and the metabolic syndrome, which include 
reduction in the levels of endogenous insulin sensitizers, such as adiponectin, and 
elevation in insulin antagonists, such as resistin, TNF-α and IL-6 (104). 
 
1.4.1 Normal insulin function and secretion 
1.4.1.1 Insulin is a peptide hormone secreted from the β cells of the pancreatic islets 
of Langerhans to maintain normal blood glucose levels by facilitating cellular 
glucose uptake, regulating carbohydrate, lipid and protein metabolism and 
promoting cell division and growth through its mitogenic effects (105).  
1.4.1.2 Mechanism of Insulin Secretion  
Synthesis and secretion of insulin is regulated by both nutrient and non-nutrient 
secretagogues, as well as environmental stimuli and the interplay of other hormones. 
Increased levels of glucose induce the glucose-mediated insulin secretion as the first 
phase by release of insulin from secretory granules in the β cell. Once glucose entry 
into  the  β  cell  is  sensed  by  glucokinase,  the  enzymes  phosphorylate  glucose  to 
glucose-6-phosphate (G6P), and generate ATP. Increase in ATP leads to closure of 
KATP-channels which results in membrane depolarization and activation of voltage 
dependent calcium channels leading to an increase in intracellular calcium 
concentration, that triggers pulsatile insulin secretion (106,107). Glucose does not 
require insulin action to enter the β cell. At the same time cyclic AMP and other 
cellular energy intermediates are also augmented, further enhancing insulin release 
(108). Other mediators of insulin release involve activation of phospholipases and 
protein kinase C (e.g. by acetycholine) and by stimulation of adenylyl cyclase 
activity and activation of β cell protein kinase A that potentiates insulin secretion. 
This latter mechanism may be activated by hormones, like vasoactive intestinal 
peptide (VIP), PACAP, GLP-1, and GIP.  These mediators appear as the second 
phase of glucose mediated insulin secretion, after refilling of secretory granules 
translocated from reserve pools (109). 
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Figure 2  Pancreatic β-cell and KATP channel. The pancreatic β-cell, the ATP-
sensitive K
+ channel (KATP channel) plays an essential role in coupling membrane 
excitability with glucose-stimulated insulin secretion. As increase in glucose 
metabolism leads to elevated intracellular [ATP]/ [ADP] ratio, closure of KATP 
channels, and membrane depolarization. The consequent activation of voltage-
dependent Ca
2+ channels causes a rise in Ca
2+ that stimulates insulin release. The 
role of pancreatic KATP  channel in insulin secretion, and elevated blood glucose 
increases  glucose  metabolism  in  the  β  cell  and  elevates  [ATP]/ [ADP]. So this 
metabolic signal closes KATP channels, which causing depolarization, activation of 
voltage-dependent Ca
2+  channels, leading to Ca
2+  entry, and insulin exocytosis. 
Various additional effectors, involving phosphatidylinositol biphosphate (PIP2) and 
Acetyl coenzyme (A acyl CoAs), act to modulate ATP sensitivity of the channel and 
can thereby affect the coupling of metabolism to secretion (Adapted from110). 
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In obesity, abnormalities in the size and distribution of fat mass are associated with 
insulin resistance,  alterations in vascular function including; low-grade chronic 
inflammation, oxidative stress, endothelial dysfunction and a pro-thrombotic 
tendency (111).  With central obesity AT synthesizes and releases increased amount 
of certain factors. These include proinflammatory chemokines and cytokines, such 
as MCP-1, macrophage migration inhibitory factor (MIF), IL-1β and IL-6 (112), 
procoagulant and proinflammatory mediators such as tissue factor (TF) and PAI-1 
(112), vasoactive substances such as angiotensinogen and endothelin-1 (ET-1) (113), 
and molecules involved in the pathogenesis of insulin resistance, such as TNF-α and 
resistin (114).  
The relationship between the adipokines and the vasculature is of increasing 
research interest, especially in obesity and its associated pathologies. Vascular 
smooth muscle (VSMC) receives numerous circulating mediators and hormones that 
exhibit vasoactive effects, some of which depend on the endothelium and others 
which act independent of the endothelium. (115). 
1.5.1 Normal vascular function 
1.5.1.1 Normal Endothelial function 
Endothelial cells form the inner lining of the vasculature. The vascular endothelium, 
besides providing a physical barrier between the lumen and the vessel wall, also 
plays an important role in the control of vascular homeostasis; the endothelium 
actively regulates the basal vascular tone and reactivity in physiological conditions. 
It plays a central role in regulating circulating factors such as hormones, fatty acids 
and nutrients to vasodilators like NO, endothelium- derived hyperpolarization factor 
[EDHF], prostaglandins [PGI2/PGE2] and to vasoconstrictors, such as, endothelin-1 
[ET-1]  (116). Gaseous NO is the most important vasodilator generated by 
endothelial cells and freely diffuses into adjacent VSMC, where it activates 
guanylate cyclase to increase cyclic GMP and evoke vasorelaxation. Binding of 
vasodilators like acetylcholine to specific G-protein coupled receptors on the surface 
of endothelial cells leads subsequently to increase in intracellular Ca
2+ levels (117) 
  35 and release of NO. The endothelium also produces vasoconstricting factors such as 
ET-1 which has both contracting and dilating properties that are mediated by at least 
two subtypes of receptors. The ETA receptor is located on vascular smooth muscle 
and mediates vasoconstriction, whereas ETB receptors are located on endothelium 
and mediate vasodilation (118). The normal regulation of vascular tone represents a 
finely tuned balance between the forces of vasoconstriction and vasorelaxation. This 
balance is regulated by both endothelium-dependent and endothelium- independent 
factors (Figure 3). 
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Figure 3 Adipokines & adipose tissue expansion. Adipose tissue expansion and its 
interaction with endothelium permeability and dysfunction induced by adipokines 
alter transendothelial transport and exclusion; which induce reduction in NO, 
hindering vasodilation, upregulation of adhesion molecules promoting immune 
infiltration and increase vessel permeability.  Leptin:  impair NO production and 
sensitivity and induce angiogenesis. TNF-α:  increases  endothelial-immune cell 
adhesion molecules and immune trafficking. Adiponectin: down regulates each of 
these responses. High concentrations of FFA: directly impair endothelial function, 
leading to further local metabolic instability.  HIF1-α: induces fibrosis in response to 
hypoxia (Adapted from 6). 
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VSMC plays an essential role in providing structural integrity of the vessel wall and 
in controlling vascular tone and blood pressure (119). VSMC is the main target of 
the effects of endothelium-released NO that stimulates the synthesis of cGMP, 
therefore preventing the Ca
2+ release from intracellular stores (120). Moreover the 
inhibition of Ca
2+-  dependent Rho/Rho kinase pathway is a relevant mechanism 
involved in the modulation of VSMC relaxation induced by the NO/cGMP/PKG 
pathway (57). The surface receptors which regulate VSMC responses and modulate 
the contractile process include those for acetylcholine, catecholamines, serotonin, 
histamine, purinergic mediators, angiotensin II (Ang II), bradykinin, neuropeptide Y, 
vasopressin, vasoactive Intestinal Polypeptide (VIP), prostanoids, leukotrienes 
oxytocin, growth factors such as Epidermal Growth Factor (EGF), PDGF, TGF-β, 
Fibroblast Growth Factor (FGF) and Insulin-like growth factor (IGF-1) (121).  
Vascular smooth muscle cells, endothelial cells and perivascular adipose tissues are 
known to contain reactive oxygen species (ROS) which might regulate ion channel 
functions. ROS are a class of oxygen- derived molecules including superoxide anion 
and hydrogen peroxide, both modulators of vascular tone (122). ROS may regulate 
cellular function by affecting ion channels, such as Ca
2＋-dependent K
＋ channels 
(123), ATP sensitive K
＋ channel (124), and Ca
2＋ channels. ROS regulates KCa3.1 
expression by modulation of the ERK and REST pathways, and influence KCa3.1 
current production in human endothelial cells. Hydrogen peroxide donor tert-butyl 
hydroperoxide (TBHP) increases KCa3.1 expression by Phosphorylated extracellular 
signal-regulated kinase (pERK) upregulation and repressor element-1-silencing 
transcription factor (REST) downregulation. In contrast, the superoxide donors 
xanthine/xanthine oxidase mixture (X/XO,) and lysophosphatidylcholine (LPC) 
decrease KCa3.1 expression by pERK downergulation and REST upregulation. In 
addition, KCa3.1 current is augmented by TBHP, and inhibited by X/XO. This 
shows that ROS play a key role in both physiological and pathological processes in 
endothelial cells by regulating KCa3.1 which induces  modulation of endothelial 
function (125). 
  38 Hydrogen peroxide accelerates the activation kinetics of Kv1.4 and Kv3.4, but not 
Kv1.3, Kv2.1 and Kv2.2 (126). It may also negatively shift the activation curve of 
Kv1.5 (127). This may explain why hydrogen peroxide is able to induce both 
vasorelaxation and vasoconstriction (128). Vasoconstriction by hydrogen peroxide is 
likely induced in a Ca
2+-dependent way, although Ca
2+  sensitization and Ca
2+-
independent pathways have also been reported (128). Superoxide anions can induce 
vasoconstriction through Ca
2+ sensitization pathways. Oxidative stress occurs when 
the production of ROS exceeds the cell’s capacity to detoxify these potentially 
injurious oxidants using antioxidant defense systems (129).   
In obese subjects several studies have showed impaired arterial vasodilation, mostly 
involving cerebral, coronary, mesenteric, and skeletal muscle vasculature. The main 
cause is endothelial dysfunction by increased secretion of proinflammatory 
cytokines, reduced levels of circulating adiponectin, and increased release of free 
fatty acids (145). All these abnormalities change gene expression and cell signaling 
in vascular endothelium, cause vascular insulin resistance, change the release of 
endothelium-derived factors, and enhanced vascular oxidative stress  (130). In 
central obesity, reduced adiponectin and elevated levels of resistin, leptin, TNFα, 
and IL-6, increases the production of superoxide anion (O2
−), which interferes with 
NO availability, thus reducing vasodilation (130). Moreover insulin resistance that 
characterizes human obesity and involves the vascular effects of hormones can 
determine per se hemodynamic consequences by impairing the balance between the 
vasodilating insulin actions exerted via the NO/cGMP/PKG pathway and the 
vasoconstricting-ones (131). However, how diseases such as insulin resistance/ type 
2 DM impact the microvasculature is still not well understood.  
1.5.2 Adipose tissue expansion and angiogenesis: 
The expansion of adipose tissue (AT) can occur through both adipocyte hyperplasia 
and hypertrophy. This expansion can lead to many effects, including hypoxia, 
adipocyte cell death, enhanced cytokine secretion, and dysregulation in fatty acid 
fluxes. 
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plasminogen activator inhibitor 1 (PAI-1) that guide preadipocyte migration toward 
developing capillary networks to ensure the coordination of the development of both 
tissues at the same place (132). Also, PPAR-γ is essential mediator for preadipocyte 
differentiation, and regulation of adipose angiogenesis (133,134). Adipose tissue 
produces several matrix metalloproteinases (MMPs) including MMP-2 and -9 that 
can potentially affect preadipocyte differentiation and microvessel maturation by 
modulating extracellular matrix (ECM) (135). MMP-9 is able to release the matrix 
bound VEGF and indirectly induces angiogenesis (136). In adipose tissue that is 
rapidly expanding, hypoxia is an important factor for vascular growth and 
remodeling (137). In response to hypoxia, adipose tissues produce hypoxia inducible 
factor-1α (HIF-1α) induced angiogenic factors like VEGF, leptin, TNF-α, and PAI-1 
that regulate angiogenesis and vasculogenesis. Thus  adipose tissue expansion is 
associated with local hypoxia, which contributes to angiogenesis by induction of a 
number of growth factors (138). 
 In the obese state, adipocyte hypertrophy creates areas of local AT micro-hypoxia at 
the earliest stages of expansion which suggest that AT is poorly oxygenated.  The 
master regulator of hypoxia and oxygen homeostasis is HIF-1α as shown in figure 4. 
Several important hypoxia-associated genes especially leptin and VEGF, are directly 
regulated by HIF-1α (139). Other adipokines such as basic fibroblast growth factor 
and IL-6 have also been shown to induce angiogenesis (140). 
Adipose tissue contains adipocytes, adipose stromal cells (ASCs), endothelial cells, 
and inflammatory cells, which produce several angiogenic factors including leptin, 
VEGF, FGF-2, HGF, IGF, TNF-α, TGF-β, VEGF-C, resistin, tissue factor (TF), and 
neuropeptide Y (NPY) (141,142,143,144,145). ASCs also  secrete high levels of 
GM-CSF (135). Recruitment of inflammatory cells also significantly contributes to 
adipose neovascularization. Activated macrophages produce potent angiogenic 
factors including TNF-α, VEGF, FGF-2, IL-1b, IL-6, and IL-8 (114). 
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Figure 4: Adipose tissue & angiogenesis. Expanding adipose depots leading to 
hypoxia which induces the upregulation of an array of adipokines, among them HIF-
1α, monocyte chemotactic protein (MCP)-1, & VEGF that necessitates angiogenesis 
for healthy tissue function.  In depots where angiogenesis progresses slowly, the 
adipose matrix becomes ﬁbrotic and induces further metabolic dysfunction (Adapted 
from 6). 
   
  41 Necrosis of adipocytes, driven by hypertrophy and accelerated by obesity, is a 
phagocytic stimulus that  regulates AT macrophage infiltration and aggregation, 
forming crown-like structures (CLSs) that surround necrotic adipocytes in advanced 
obesity (146). Adipose tissue macrophages serve multiple functions including 
removal of necrotic adipocytes leading to lipid-engulfed foam cells, performing as 
proinflammatory mediators, and serving as angiogenic precursors (6).  
Leptin is a potent angiogenic factor, and the expression of the functional long form 
of leptin receptor (OB-Rb) in endothelial cells has led to the discovery of its 
angiogenic activity (147). Leptin could also  indirectly induce angiogenesis via 
upregulation of VEGF mRNA expression via activation of the Jak/Stat3 signaling 
pathway (148). Resistin is also defined as an angiogenic factor, which directly 
promotes endothelial cell proliferation, migration, and tube formation (145).  
Fatty acids stored in the form of triglycerides,  are released from hypertrophic 
adipocytes through lipolysis during fasting. Some of FFAs are shunted to the liver 
and stored in lipid droplets and many of them are locally re-esterified in adipocytes 
(149). Those FFAs that escape re-esterification play a critical role in several organs 
as a primary energy source during prolonged fasting (150). They also serve as 
ligands for the toll like receptor (TLR4) complex which activates the classical 
inflammatory responses by increasing local extracellular lipid concentrations, 
thereby ultimately driving AT macrophage accumulation (151). So either high rates 
of lipolysis or an influx of saturated FFAs into adipocytes can cause temporary 
inflammation within the tissue (152).  
1.5.2.1 Healthy and pathologic angiogenesis:  
Recent studies suggest that the balance between angiogenesis and hypoxia has a 
significant impact on the modulation of “good/healthy” versus “bad/unhealthy” 
tissue expansion, thereby involving the local microvasculature as a key modulator of 
the systemic impact of adipose depots (6).  The  vasculature serves to transport 
systemic lipids to their storage depot in the adipocytes and adipokines and nutrients 
such as FFAs from these cells to other tissues in time of metabolic need.  So 
expansion and contraction of fat mass relies on the adipose tissue circulation (153). 
Therefore insufficient circulation  results in local hypoxia which leads to up-
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expression of angiogenic adipokines such as, VEGF, hepatocyte growth factor and 
PAI-1  (101), which promote vascular endothelial cell proliferation and the latter 
stages of new vessel formation. Also, increased levels of HIF1-α leads to an up-
regulation of the inflammatory adipokines (IL–6, TNF-α, and MCP-1) (6). These 
pro-inflammatory secretory products enhance insulin resistance, and induce adipose 
tissue fibrosis that leads to further adipose dysfunction as shown in figure 5. 
1.5.2.2 Microvascular dysfunction in Obesity and Insulin Resistance: 
The vasodilator actions of insulin involve the endothelial insulin receptor, insulin 
receptor substrate 1 and receptor substrate 2 (IRS1 and IRS2), PI3-kinase, 
phosphoinositide-dependent kinase 1 (PDK-1), and protein kinase B (Akt) (154, 
155).  Insulin-induced stimulation of Akt directly increases endothelial NO 
production via endothelial nitric oxide synthase (eNOS). The metabolic action of 
insulin to stimulate glucose uptake in skeletal muscle and adipose tissue is mediated 
through stimulation of similar PI3-kinase–dependent signaling pathways  beside 
these vasodilators actions.  The vasoconstrictor effects are mainly mediated by the 
vasoconstrictor peptide ET- 1 (154). ET-1 is produced in the vascular endothelium 
through stimulation of the intracellular mitogen-active protein kinase (MAPK) 
signaling pathway and the extracellular signal-regulated kinase-1/2 (ERK1/2) as 
shown in figure 6 (59). The key feature of insulin resistance is that it is characterized 
by specific impairment in PI3K-dependent signaling pathways, while insulin’s 
signaling through the MAPK pathways remains intact (Figure 6) (155). 
The obese insulin-resistant individual suffers impairments in the microvasculature. 
The existence of microvessel endothelial dysfunction has been established by 
blunted NO-mediated vasodilator responses in skin and resistance arterioles to 
classic endothelium-dependent vasodilators. Impaired capillary recruitment to 
reactive hyperemia has also been reported (156).  
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Figure 5: Adipose tissue expansion. Healthy adipose depot expansion comprises 
enlargement in tissues through effective and adequate angiogenic response and 
appropriate remodeling of the ECM. While, pathological adipose depot expansion 
comprises huge enlargement of existing adipocytes, limited angiogenesis, and 
hypoxia lead to induction of HIF-1α, which in turn can cause induction of fibrotic. 
Ultimately, M1 stage macrophage leading to an inflammation which is associated 
with systemic insulin resistance (Adapted from 23). 
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Figure  6:  Insulin resistance mechanism.  The interactions between endothelial, 
smooth muscle (SM) and adventitial cells. In conditions of insulin resistance the 
balance between vasoconstrictor and vasodilator pathways is shifted towards a 
predominant vasoconstriction. Moreover, the impairment of adipocyte function and 
production of inflammatory cytokines within the perivascular adipose tissue leads to 
increase ROS production and oxidative stress that, increases smooth muscle cell 
contractility (Adapted from 214). 
 
 
  45 1.5.2.3 Microvascular dysfunction and type 2 diabetes: 
β-cell dysfunction was thought to be the most important risk factor for type 2 
diabetes in normoglycemic subjects. However, more recent evidence suggests that a 
combination of both insulin resistance and relatively diminished insulin secretory 
function of pancreatic β-cells (157) play a part in the disease. Expansion of β-cell 
mass has been reported in obese subjects and is related to increased intake of 
nutrients (glucose and FFAs). As the insulin resistance increases, insulin production 
also increases in concert. However if these processes are not coordinated diabetes 
will ensue. Low adiponectin and elevated levels of other adipokines such as, leptin, 
TNF-α,  and  IL-6 are also associated with an increased risk of diabetes. This 
probably relates to their effects on both insulin sensitivity and the pancreas leading 
to β-cell failure (158,159). 
Diabetes alters the function of various cell types, including the endothelium, smooth 
muscle cells and platelets. The disease impairs endothelium dependent vasodilation 
(NO mediated) by a number of fundamental mechanisms, such as hyperglycemia, 
dyslipidemia and insulin resistance, which lead to decreased endothelium derived 
NO, (160). Hyperglycemia inhibits production of NO by blocking eNOS synthase 
activation and inducing reactive O2 production, in particular superoxide anion (O2
-) 
in endothelial and VSMC (161). Circulating levels of free fatty acids are elevated in 
diabetes and insulin resistance due to their excess release from adipose tissue and 
diminished uptake by skeletal muscle (162,158). Free fatty acids impair endothelial 
function through increased production of oxygen-derived free radicals, activation of 
PKC, and exacerbation of dyslipidemia (163). Elevation of free fatty acid 
concentrations activate PKC and decrease insulin receptor substrate-1–associated 
phosphatidylinosital-3 kinase activity (164). These effects on signal transduction 
may decrease NOS. In insulin-resistant peoples, endothelium-dependent vasodilation 
is reduced (165). Abnormal endothelium-dependent vasodilation in insulin-resistant 
states is due to alterations in intracellular signaling that reduces the production of 
NO. In particular, insulin signal transduction through the Pl-3 kinase pathway is 
impaired, and insulin is less able to activate NOS and produce NO. Abdominal 
adipose tissue, which is prominent in type 2 diabetes, is more insulin resistant and 
  46 releases more free fatty acids compared with the type of adipose in other locations 
(98). Thus, free fatty acid–induced alterations in intracellular signaling also 
contribute to decreased NOS activity and reduced production of NO in insulin-
resistance. In diabetes, endothelial cell dysfunction is not only by decreased NO but 
also by increased synthesis of vasoconstrictor prostanoids and endothelin (161). 
Endothelin-1 activates endothelin A receptors on VSMC to enhance 
vasoconstriction. Dysregulation of vascular smooth muscle function is exacerbated 
by impairments in sympathetic nervous system function (166). Diabetes also induces 
PKC activity, NF-κβ production, and generation of oxygen-derived free radicals in 
VSMC, similar to the effects in endothelial cells (155). 
1.6 Ion Channels of adipose tissue 
Ion channels are protein molecules present as pores in the plasma membrane and 
membranes of intracellular organelles of all cells. They play an important role in 
maintaining cellular integrity, excitation, smooth muscle contraction, secretion of 
hormones and neurotransmitters. These channels use the ionic gradient between the 
cytosolic and extracellular spaces  to transfer sodium (Na
+), Potassium (K
+), and 
calcium (Ca
+) ions, and regulate the shape and frequency of action potentials in 
skeletal muscle, cardiac muscle, smooth muscle  and neurons. They restore the 
balance of ions across a membrane and the difference in voltage occurs across that 
membrane creating a membrane potential, when ions are present in a higher 
concentration on one side of a membrane than the other. So ion channels open in 
response to a change in membrane potential, allowing the ions to move from the side 
of the membrane with the higher ion concentration to the side with the lower ion 
concentration (91). 
Adipocytes are pivotal in imparting the endocrine organ of adipose tissue as well as 
metabolism, storage and effects of fatty acids. Electrophysiological and molecular 
evidence show that several ion channels can be found in adipocytes and adipose 
tissue. These include Ca
+ and K
+ channels as well as selective and non-selective ion 
transporters as represented in figure 7.  
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Figure 7: Types of ion channels described in adipocytes. From the literature these 
were the ion channels that have been described in vessels isolated from the adipose 
tissue. L: Long lasting-type Ca
2+ channels. T: Transient-type Ca
2+ channels. KATP: 
Adenosine-triphosphate-sensitive  potassium channel. KDR: Delayed rectifier 
potassium channel. 4AP: Aminopyridine sensitive potassium channel. NS: Non 
selective channel. K
+/Na ATPase
+: Ion transport/pump systems.  
 
 
   
  48 The voltage–activated (Kv), adenosine-triphosphate-sensitive (KATP) and calcium-
activated (KCa) have been described in adipose tissue. In a recent study Kv7.1 was 
identified as the active isoform of Kv found in vessels embedded in human adipose 
tissue (167). The inhibitory action of the newly described but yet unidentified 
adipocyte-derived relaxant factor (ADRF) is reportedly mediated by tyrosine kinase 
pathways and opening of KATP channels (8) in the aorta. In rat mesenteric arteries, 
the vasodilatory effect of perivascular fat involves the activation of Kv channels 
(168). Interestingly, the channels activated by fat in mesenteric arteries (Kv) differ 
from the channels proposed to be activated in the aorta (KATP) suggesting that there 
are vascular regional differences in the effects of perivascular adipose tissue on ion 
channels (Figure 6). 
Potassium channels (K
+) is the most abundant, diverse one of these channels and its 
activity is regulated by voltage, calcium and neurotransmitters. This channel plays 
an important role in maintaining the normal physiological cellular process in the 
body, especially smooth muscle relaxation, immune function and insulin secretion 
(169,170).     
1.6.1 Vascular ion Channel and insulin resistance/obesity:  
Vascular ion channels generally contribute to the excitability and reactivity of blood 
vessels. In VSMCs, potassium (K
+) channels situated in the plasmalemma play a 
fundamental role in maintaining the membrane potential, which is a major 
determinant of vascular tone, particularly in systemic resistance vessels.  The 
membrane potential is determined by membrane permeability to several ions, 
including K
+, Ca
2+, Na
+, and Cl
− ions. Ion transport systems such as the Na
+/K
+ 
pump or anion transporters can also contribute. The blockade of K
+ channels results 
in membrane depolarization and increased Ca
2+ influx through voltage-operated Ca
2+ 
channels (VOCCs), leading to vasoconstriction.  On the other hand the activation of 
K
+ channels results in plasmalemmal K efflux, membrane hyperpolarization, and 
reduced Ca
2+ influx through VOCCs, leading to vasodilation (171). Altered vascular 
K
+ channel function has been reported under pathological conditions and during 
major cardiovascular diseases like chronic hypertension, diabetes and 
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dilate are likely consequences of defective K
+ channel function in blood vessels and 
may be due to a change in the number, unitary conductance, and/or exposed 
probability of the channels (172). 
Activation of calcium channels by adipokines has been described. Both L- and T-
type plasmalemmal Ca
2+ channels have been described for the human subcutaneous 
adipose vessels (173). Changes in cytosolic Ca
2+  concentration are the principle 
mechanism that  regulates the contractile state of VSMCs. In response to 
vasoconstrictor stimuli, calcium accumulation occurs by release from intracellular 
stores such as the sarcoplasmic reticulum and/or influx through various types of Ca
2+ 
channels to increase the cytosolic Ca
2+ concentration in VSMCs (174). The increases 
in intracellular calcium are also known to activate mitogen-activated protein kinases 
that are involved in smooth muscle contraction by increasing the sensitivity of the 
contractile apparatus to calcium (175). Initial rise in intracellular calcium inhibits Kv 
channels, which results in membrane depolarization and subsequent activation of 
voltage-gated calcium channels in which calcium influx then leads to myosin light 
chain phosphorylation and smooth muscle contraction (176).  
The intermediate conductance calcium-activated potassium channel KCa3.1 
(KCNN4 and IKCa), contributes to a variety of cell activation processes in 
pathologies like inflammation, carcinogenesis, and vascular remodeling (177). 
KCa3.1 is a member of the calcium-activated potassium channel (KCa) 4 family, 
tightly binds the Ca
2+  sensor calmodulin near its C-terminal domain. KCa3.1 is 
opened when there is a small rise in free cytosolic Ca
2+  ([Ca
2+]i) due to Ca
2+-
calmodulin-mediated cross-linking in the subunits of the channel tetramer (178). 
Channel activation induces membrane hyperpolarization that promotes Ca
2+ influx, 
and increase in KCa3.1 expression has been associated with cancer development, 
immune disorders, and vascular inflammation. The electrophysiological and 
transcriptional mechanisms of VSMCs; shows change as they proliferate and in the 
contractile form.  Ca
2+  influx through voltage-dependent Ca
2+  channels causes 
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turn induces Ca
2+ channel closure through repolarization (177).  
Potassium and calcium channels play an important role in mediating the hypoxic 
response of blood vessels (176). Hypoxia has also been shown to block outward 
potassium current that results in membrane depolarization (179). Hypoxia increases 
reduced  β-nicotinamide adenine dinucleotide  levels that activates adenosine 
diphosphate-ribosyl cyclase and inhibits cyclic adenosine diphosphate-ribose 
hydrolase. This leads to accumulation of cyclic adenosine diphosphate-ribose that 
stimulates calcium release from the sarcoplasmic reticulum and subsequent events 
leading to vasoconstriction (85).  
Insulin resistance in obesity and hypertension is associated with impairment of 
insulin-mediated ion exchange processes (Ca
2+-ATPase and Na
+, K
+-ATPase), 
leading to Ca
2+ and Na
+ accumulation on the vascular wall (180). This alteration 
facilitates the action of vasoconstrictor agents such as Ang II and norepinephrine 
(181). Insulin resistance is accompanied by endothelial dysfunction in experimental 
models of hypertension in resistance vessels with impaired PI3-kinase-dependent 
NO production and enhanced ET-1 secretion that may combine with elevated 
peripheral vascular resistance and contribute to hypertension in this model (182). 
1.6.2 Vascular studies on the human vessels 
Central obesity and accumulation of intra-abdominal visceral fat are linked to 
cardiometabolic risk, by increased elaboration of proatherogenic mediators from the 
visceral adipose microenvironment which are toxic to the vasculature due to 
upregulation of proinflammatory, oxidative-stress related, and hypoxia-induced 
adipocytokines that severely impair arteriolar endothelial vasodilator function in 
visceral compared to subcutaneous depots (183). A recent study demonstrated 
upregulated expression of transcripts involving the cyclooxygenase pathway, which 
is involved in the production of vasoconstrictive prostanoids and reactive oxygen 
species known to impair vascular tone and typical of obesity-related conditions such 
as diabetes, hypertension, and atherosclerosis. The imbalance between endothelium 
derived constrictive and relaxing factors that exists in visceral depot, is in part due to 
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vascular tone (184).  
In healthy people, PVAT modulates the contractile tone of adjacent small arteries by 
secreting vasodilatory molecules that act independently of the endothelium and 
include adiponectin, NO, and hydrogen sulfide. The first human small artery study 
of PVAT was performed in 2009 and showed that subcutaneous gluteal PVAT from 
lean healthy individuals reduced adrenergic constriction in adjacent arteries, an 
“anticontractile” effect (175). In metabolic syndrome patients the vasodilatory effect 
of the PVAT was entirely lost, due to dual processes of adipose tissue hypoxia and 
inflammation, both of which are established sequel of obesity in fat depots (26). 
Recently it was shown that macrophage activation in adipose tissue contributes to 
the attenuation in PVAT anticontractile effect (185).  
1.7 Effect of Bariatric surgery on human: 
Bariatric surgery is performed to achieve both significant and sustained weight-loss 
in severely obese patients, improves cardiovascular risk profiles and reduces overall 
mortality. The improvements in weight, blood pressure, inflammation, and 
metabolism overall reverse the obesity-induced alteration to adipose tissue 
anticontractile function (186). These reversals are due to reductions in local adipose 
inflammation and oxidative stress with improved adiponectin and nitric oxide 
bioavailability (186). There are 3 types of bariatric surgical procedures: restrictive, 
malabsorptive, and combined operations (187). Gastric bypass surgery is a 
combination of restriction and malabsorption and achieves a significantly higher 
degree of weight loss than restrictive bariatric surgery as shown in figure 8 (188). 
A study that investigated the effect of bariatric surgery on the vasodilatory properties 
of PVAT showed 3 main findings. Firstly, bariatric surgery reversed the damage 
induced by obesity to PVAT anticontractile function. Secondly the PVAT functional 
recovery was  independent of the endothelium. Thirdly  bariatric surgery restored 
PVAT function by reducing adipose inflammation and increasing local adiponectin 
and NO bioavailability (186). 
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Figure 8:  Types of bariatric surgery. Three types of bariatric surgery: Sleeve 
gastrectomy, band gastroplasty, and gastric bypass. Gastric bypass is a combination 
of restriction and malabsorption, this type of surgery achieved higher degree of 
weight loss than others (Adapted from: www.nationalbariatriclink.org). 
 
   
  53 1.8 Heterogeneity of the obese population   
The majority of normal weight or lean individuals have normal metabolic function, 
normal adipokine levels,  including adiponectin and their macrophages express 
markers of M2 (alternatively activated state) as shown in the figure 9. As obesity 
develops, adipocytes undergo hypertrophy owing to increased triglyceride storage. 
The expansion of adipose tissue promotes the transition to obesity accompanied by 
metabolic dysfunction, as well as generation of large amounts of pro-inflammatory 
factors such as, leptin, resistin, retinol-binding protein 4 (RBP4), lipocalin 2, 
angiopoietin-like protein 2 (ANGPTL2), TNF-α, IL-6, IL-18, CC-chemokine ligand 
2 (CCL2), CXC-chemokine ligand 5 (CXCL5) and nicotinamide 
phosphoribosyltransferase (NAMPT) (189,  190). Obesity, when associated with 
mild metabolic dysfunction exhibit improved metabolic parameters, diminished 
inflammatory marker expression and better vascular function, when compared with 
obesity associated with full metabolic dysfunction.  
Therefore the presence of metabolic abnormalities varies even between equally 
obese individuals, with some of them being protected or resistant to the development 
of metabolic abnormalities (Figure 10;191) and others less so. The former 
individuals, defined as metabolically healthy but obese (MHO), have excessive body 
subcutaneous fat accumulation and display  a favorable metabolic profile 
characterized by high levels of insulin sensitivity, no hypertension, as well as, a 
favorable lipid, inflammation, hormonal, liver enzyme and immune profile (192). 
Khittle et al found that about 20% of obese individuals do not have metabolic 
abnormalities and healthy obese appear to have less clustering of CVD risk factors 
(193).  Overall,  healthy obesity  describes the absence  of any metabolic disorder 
including type 2 diabetes, dyslipidemia and hypertension. The existence of distinct 
group MHO lead to more precise definition of healthy obesity which represents the 
continuous relationship between increasing BMI and by using specific parameters 
for different metabolic syndrome components such as blood pressure, fasting insulin 
levels, HDL and triglycerides. So this group remains insulin sensitive and 
metabolically healthy. In their study Stefan et al (194) divided their subjects into 3 
  54 groups – normal weight, obese-insulin sensitive, and obese-insulin resistant, and also 
examined cardiovascular risk factors. They found, the obese-insulin sensitive group 
had intimal medial thicknesses similar to that seen in the normal weight group and 
when compared to the insulin resistant group, had less skeletal muscle fat, less 
hepatic fat deposits, and lower intimal-media thickness of the common carotid 
artery, giving them a more favorable risk profile despite similar weights. For thus, it 
appears that in some limited circumstances, the adipose tissue has a greater ability to 
expand without the associated metabolic stress that triggers pro-inflammatory 
cytokine production and downstream effects such as insulin resistance (194).          
This healthier metabolic profile may not necessarily translate into a lower risk for 
cardiovascular mortality. It might just reflect a transition stage, prior to conversion 
to the pathologically obese (PO) state.  The mechanisms that could explain the 
differences between the metabolic profile of MHO and PO individuals are poorly 
understood. Preliminary evidence suggests that differences in visceral fat 
accumulation, birth weight, and adipose cell size and gene expression-encoding 
markers of adipose cell differentiation may explain the development of the MHO 
phenotype (195). 
 
The growing incidence of obesity and type 2 diabetes mellitus is a worldwide 
epidemic problem and now recognized as one of the most challenging threats to 
public health  (196).  In the setting of obesity, the  accumulation of fat tissue 
associated with excess fatty acid secretion, increased production of inflammatory 
cytokines and abnormal adipocyte hormone signaling leading to insulin resistance 
and chronic inflammation is postulated to play a role in development of type 2 
diabetes and other obesity-related comorbidities (1,2). Elevated levels of fatty acids 
are commonly seen in obesity and diabetes and lead to diminished utilization of 
whole body glucose and cardiac muscle glucose and diminished skeletal muscle 
(197). In addition, increased circulating fatty acids levels lead to reduced beta cell 
function with diminished insulin secretion  (198).  In the pathology of diabetes, 
inflammation plays a role in disease development and progression in adipose tissue, 
liver, and skeletal muscle by provoking insulin resistance and beta cell dysfunction. 
  55 So  the  combination of insulin resistance and beta cell dysfunction,  which 
characterizes diabetes. Several of inflammatory markers have been associated with 
diabetes including CRP, IL-6, MCP-1, IL-8, and PAI-1 (199). 
Central  obesity has  been shown to have a greater association with diabetes or 
metabolic syndrome, as opposed to overall obesity (200). Visceral depot has more 
significant impact on diabetes related risk factors than that found in SC depots (200). 
Thus, uncontrolled diabetes leads to macrovascular and microvascular 
complications, like myocardial infarction, stroke, blindness, neuropathy, and renal 
failure in many patients. The main aim of current medical treatment is to halt disease 
progression by reducing hyperglycemia, hypertension, dyslipidemia, and other 
cardiovascular risk factors (201). 
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Figure 9: Heterogeneity of fat tissue. Adipose tissue can be described in three 
structural and functional classifications: lean with normal metabolic function, obese 
with mild metabolic dysfunction and obese with full metabolic dysfunction (Adapted 
from 13). 
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Figure 10: Clinical characteristics of MHO and PO patients 
 
 
 
 
  58 1.9 Hypothesis  
 
The subcutaneous adipocyte dysfunction and inflammation have been reported along 
with adipocyte hypertrophy  in pathological obese (PO) and diabetic obese (DO) 
subjects. The enlarged adipocytes are more susceptible to hypoxia due to changes in 
vascular tone and decreased capillary density of the depot. Hypoxia will leads to cell 
necrosis and the formation of immunological foci. The more hypoxic and inflamed 
fat depot secretes less adiponectin, which then may determine the increased systemic 
insulin resistance and dyslipidaemia seen in the PO and DO vs metabolically healthy 
obese (MHO).  
 
1.9.1 Aim 
Specifically, differences between MHO, PO and DO in relation to vascular function 
were determined. 
 
1.9.2 Objectives:  
•  A cohort of MHO, PO and DO subjects were identified.  
•  Vascular differences in the adipose tissue of MHO versus PO versus DO by 
functional studies (myography) and histological assessment were carried out. 
•  Mechanisms that underlie these differences and dysfunctions were assessed.  
•  Different key pathways were investigated such as NO, COX, and EDHF.  
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Chapter 2 
Materials & Methodology 
 
 
 
 
 
 
   
  60 2.0 Methods 
2.1 Patient recruitment and classification:  
The study was approved by the Ethics Committees of Shafallah Medical Genetics 
Center, Doha, Qatar and written informed consent was obtained from all 
participants. Sixty three Qatari patients with BMI>40kg/m
2 undergoing laparoscopic 
bariatric surgery for weight loss were recruited from the pre-operative clinic at Al-
Emadi Hospital  and Hamad medical corporation (HMC).  Patients with known 
coronary artery disease, uncontrolled hypertension, malignancy or terminal illness, 
connective tissue disease or other inflammatory conditions likely to affect cytokine 
levels, compromise immune function or those with substance abuse or other causes 
for poor compliance were excluded.  
Currently there are no WHO criteria defining the levels for hyperinsulinaemia. 
However previous studies, by Mohamed-Ali et al., (202) reported value of 5.9 to 6.7 
µU/ml, and the Framingham study reported insulin levels of 7.5 µU/ml (203) in 
healthy people.  8 µU/ml of insulin was chosen as the cut-off in the current study as 
this produced two distinct metabolic popoulations. Thus, MHO subjects were 
defined as those with insulin < 8 µU/ml (normoinsulinaemia) and PO as those with 
insulin > 8.0 µU/ml (hyperinsulinaemia) (Table 1). 
2.1.1 Anthropometric measurements:  
Body mass index (BMI) was calculated as the weight (kg) divided by the square of 
0the height (m
2). Blood pressure was measured with a digital blood pressure 
monitor. All these measurements were taken at Al-Emadi Hospital and HMC.  
2.1.2 Blood and Adipose tissue collection:  
Following an overnight fast, blood samples were obtained from an ante-cubital vein 
on the day of the operation immediately after anesthesia, separated into plasma and 
cells and stored at -80 
oC until analysis. During the surgery, adipose tissues from the 
abdominal subcutaneous and intra-abdominal omental tissues were obtained (~5g 
each) and quickly transported in serum-free medium (Cellgro, Mediatech Manassas, 
VA) to the laboratory. 
  61 2.2 Determination of vascular reactivity by Myography 
Micro-myography was used to investigate  reactivity  of arterioles/small arteries 
isolated from both SC and OM. This process consists of several steps; dissection, 
mounting, normalization to put the vessel under appropriate pre-tension & checking 
viability of the vessel prior to conducting experiments.  
Adipose tissues surrounding the blood vessels were carefully removed under a 
dissecting microscope. Since arteries and veins commonly run parallel to each other, 
the arteries were distinguished from veins by their relatively smaller size, greater 
firmness, as well as V shaped branching (Figure 11B). The arteries were cut into 
segments (~2 mm long) ready for mounting in normal physiological salt solution 
(PSS). The normal PSS contained (in mM) 112 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 25 
NaHCO3, 0.5 KH2PO3, 0.5 NaH2PO3, and 10 glucose (gassed with 95% O2 / 5% CO2 
to pH 7.4).  
2.2.1 Dissection: 
The first step of vessel preparation was to distinguish artery from vein. There were 3 
major differences between artery and vein in human AT: (1). the branch of the artery 
is seen as “V shaped: while the branch of the vein was “U-shaped”; (2) the lumen 
size of artery is apparently smaller compared to the vein; (3) the blood flow was 
faster in artery versus vein (Figure.11). After carefully dissecting the surrounding 
AT, arterioles were isolated under a dissecting microscope and cut into segments (~2 
mm long). 
2.2.2 Mounting:  
A  mounting wire with length of ~2.2 cm was 1
st  attached to the jaws of the 
myograph and clamped. Using forceps the vessel was held close to the proximal end, 
and pulled over the wire. A second wire was then inserted and aligned in parallel 
with the 1
st within the vessel (Figure 12). The ends of the wires were then screwed 
onto the left and right nuts on the mounting jaws as shown in figure 12. 
  62 2.2.3 Normalization:  
Normalisation procedure was carried out automatically under transmural pressure of 
100 mmHg to put the vessel under appropriate pretension and determine the internal 
diameter (ID) for each vessel mounted on the myograph. The ID for OM vessels 
averaged 250±16 µm and for SC was 244±40 µm.  
2.2.4 Equilibration period and test of viability:  
Following normalization, each vessel was allowed an equilibration period of at least 
1hr. During this time, the vessel was challenged with high KCl (90 mM) and NA (10 
µM) to optimize its response. The ability of the isolated arterioles to contract (at 
least up to 1 mN) in response to the 90 mM KCl was used as an index of vessel 
viability. Vessels that generated less than 1 mN force were discarded. 
2.2.5 Experiment protocol:  
Following equilibration, vasoconstriction was assessed by constructing cumulative 
concentration-response curves for KCl (1 to 70 mM; non receptor depolarization- 
dependent contractile agent)  or  NA  (10
-9  to 10
-4.5  M; sympathomimetic and 
adrenergic receptor agonist).    Vasorelaxation was assessed by constructing 
cumulative relaxation response curves  for  Acetylcholine (Ach, 10
-9  to 10
-4.5  M; 
classical endothelium-dependent relaxant), Prostaglandin E2 (PGE2) -10
-9 to 10
-4.5 M 
or  Sodium Nitroprusside (SNP,  10
-9  to 10
-4.5  M; NO donor and endothelium 
independent relaxant). Up to 2 curves were obtained per vessel segment separated by 
a washout period of 30–60 min. With this protocol, there was no apparent time-
dependent change in the response to any of the vasoconstrictors or vasorelaxants. In 
most cases vessels from SC and OM depots from the same patients were tested in 
the same chamber at the same time.  
To assess mechanisms of responses some agonists were tested in the presence of 
respective anatagonist. L-NAME  (100μM)  for  mediators  of  endothelium  NO, 
apamine (0.5μM) and charybdotoxin (0.1μM) for EDHF, indomethacin (10μM) for 
COX (COX1 & COX2), barium chloride (30μM) for Kir channel.  
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Figure 11B: 
 
 
 
Figure 11: Identification of blood vessels within the omental adipose tissue.   (A) 
Artery and vein as seen within the omental adipose tissue. (B) Typical “V” shaped 
branching for artery and “U” shaped for vein. These pictures were taken with camera 
on a microscope (A) and camera alone (B). 
Artery  Vein 
V-shaped 
U-shaped 
Vein 
Artery 
Adipocyte 
U-shaped  V-shaped 
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Figure 12: Mounting of vessels on a wire myography. A-D shows the main steps 
of vessel mounting (DMT User Manual). E and F pictures were taken from our 
preparation in our lab. 
 
 
 
  65 2.3 mRNA expressions 
RNA extraction was performed using Trizol-Chloroform extraction method. 
Adipose tissue (0.5-1g) was used either directly or collagenase digested to produce 
separate fractions (stromal vascular fraction; SVF, and mature adipocytes) and then 
used for RNA extraction.  
2.3.1 Collagenase digestion protocol: 
Adipose tissue biopsies (1-2g) was washed with warm PBS containing 1% antibiotic 
solution then minced into small pieces. Tissues were then digested using freshly 
made collagenase solution (0.1% collagenase I/1% BSA in PBS). Adipocytes were 
separated from SVF after centrifugation at 400g for 10 min and mature adipocytes 
were collected for further analysis. Erythrocytes were removed by resuspension of 
SVF pellets in lysis buffer (2.06 mg/ml Tris base, pH 7.2, 7.49 mg/ml NH4Cl) for 10 
min. After centrifugation, the pellets were resuspended in HBSS containing 2% fetal 
bovine serum (FBS) and filtered through a 70uM and 40uM sieves. 
2.3.2 RNA extraction protocol: 
Trizol (0.8 ml) was added to the pelleted SVF or mature adipocytes fraction that was 
obtained from 1g collagenase digested adipose tissue.  This was followed by mixing 
on a vortex (10 cycles of 5 seconds each and separated by 5 seconds). Chloroform 
(1/10 of recorded volume) was then added, followed by 15 seconds of mixing on a 
vortex and incubation for 5 minutes on ice. This was followed by centrifugation for 
15 minutes at 14,000 rpm and 4
oC.  Aqueous phase was then collected and equal 
volume of isopropanol was added. Samples were left at -20 
oC for 1.5 hours, then 
centrifuged for 15 minutes at 14,000 rpm at 4
oC. Isopropanol was then removed very 
carefully and the  pellet washed three times  with 0.8 ml of 75% ethanol,  by 
centrifugation for 5 minutes at 14,000 rpm at 4
oC. After the last wash, ethanol was 
removed carefully and the pellet was air dried on ice with cling film on top and 
Eppendorf  lid  left  open for 10 minutes. The pellet was resuspended  in 45µl of 
DEPC/H2O and left at room temperature for 10 minutes, then mixed by vortex and 
left on ice for 10 minutes. Purity was assessed and aliquots were stored at -80C 
(3x15µl aliquots).  
  66 From 200-500 ng RNA, cDNA was synthesized using Reverse Transcription 
Reagent Kit (Applied Biosystems, New Jersey, and USA) and followed by Real-
time PCR (Taqman, Applied Biosystems, and Califonia, US). The mRNA 
expression of genes related to vascular function such as adrenoceptors (α 1), ion 
channels (K
+ & Ca
2+ channels) and components of the NOS and COX pathway were 
investigated. Following assessment of RNA purity/quantity  with a Nanodrop 
spectrophotometer, the expression of β-actin was used as the ‘house-keeping’ gene, 
as  an additional indicator for RNA yield and quality  and PCR efficiency. All 
samples showing β-actin CT higher than 25 were excluded. 
2.3.3 cDNA Synthesis: 
cDNA was synthesized from one microgram of RNA using Applied Biosystems Inc 
(ABI) high capacity cDNA RT kit according to manufacturer’s instructions. Briefly, 
the amounts of buffer, MgCl2, dNTPs, Oligo d(T)16 and RNase inhibitor required for 
the total reaction volume for all samples were calculated to make up the master mix. 
The required volume of master mix was then added to each tube with 200ng-1000ng 
of RNA per sample. Reverse transcriptase was finally added and reverse 
transcription was carried out by incubating samples for 2 hours at 37
oC on PCR 
machine.  cDNA samples were then stored at -20
oC. 
2.3.4 Real Time-PCR 
RT-PCR was performed using RT² SYBR® Green qPCR (ABI, USA) using the 
following protocol. 
1. The following components were added in a PCR tube: (RT² SYBR® Green qPCR 
Mastermix, ddH2O, template cDNA (up to 250 ng), gene-specific 10 µM PCR 
primer pair stock). 
2. RT-PCR was performed using 95ºC, 10 min; 40 cycles of (95ºC, 15 sec; and 
60ºC, 60 sec) on ViiA7 (ABI, USA).  
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2 Profiler PCR Array   
In order to assess the expression of hypertension-related genes, R
2 Profiler PCR 
Array (Human hypertension PAHS-037Z) was utilized according to manufacturer’s 
instructions (Qiagen, UK).  
2.3.5.1 Procedure: 
Reagents were thawed at room temperature and briefly centrifuged (10– 15 s) to 
bring the contents to the bottom of the tubes. The genomic DNA elimination mix for 
each RNA sample was prepared, mixed gently and centrifuged briefly according to 
the Table below:  
Genomic DNA elimination mix 
The genomic DNA elimination mix (RNA 25 ng–5 µg, Buffer GE 2 µl, RNase-free 
water to be added to reach 10 µl the total volume) was incubated for 5 min at 42°C, 
then immediately placed on ice for at least 1 min. The reverse-transcription mix (5x 
Buffer BC3 (4 µl), Control P (2 1 µl), RE3 Reverse Transcriptase Mix (2 µl), 
RNase-free water (3 µl)) multiplied according to the number of the reactions was 
prepared.  
10 µl reverse-transcription mix was added and mixed gently to each tube containing 
10 µl genomic DNA elimination mix, incubated at 42°C for exactly 15 min and then 
the reaction stopped immediately by incubating at 95°C for 5 min.  91 µl of RNase-
free water was added to each reaction. The reaction mixture was placed on ice and 
then analysed with the real-time PCR protocol. 
2.3.5.2 RT
2 PCR Procedure: 
Briefly, the RT
2 SYBR Green Master mix (10–15 s) was centrifuged to bring the 
contents to the bottom of the tube. The PCR components mix was prepared in a 5 ml 
tube or a loading reservoir depending on the RT
2 Profiler PCR Array format, as 
described below: 
Formats A, C, D, or F (96-well). The RT
2 Profiler PCR Array was removed carefully 
from its sealed bag. 25 µl PCR components mix of 2x RT
2SYBR Green Mastermix 
(1350 µl), cDNA synthesis reaction (102 µl), and RNase-free water (1248 µl) was 
added to each well of the RT
2 Profiler PCR Array using an 8-channel pipette, or a 
  68 12-channel pipette  using only 8 tips. The RT
2  Profiler PCR Array was sealed 
carefully with Optical Thin Wall 8-Cap Strips (Formats A and D) or Optical 
Adhesive Film (Formats C, E, F, and G) and centrifuged for 1 min at 1000 g at room 
temperature (15–25°C) to remove bubbles. The plates were visually inspected from 
underneath to ensure no bubbles were present in the wells.  The RT
2 Profiler PCR 
Array was placed on ice while setting up the PCR cycling program. The real-time 
cycler was programmed according to the ViiA7 (ABI, USA). 
 
 
The array plate format and the list of genes studied are shown below. 
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  69 Position  UniGene   GenBank   Symbol   Description 
A01     Hs.654434   NM_000789  ACE     Angiotensin I converting enzyme  
A02     Hs.178098   NM_021804   ACE2     Angiotensin I converting enzyme 2 
A03     Hs.500483   NM_001613   ACTA2     Actin, alpha 2, smooth muscle, aorta 
A04     Hs.441047   NM_001124   ADM     Adrenomedullin 
A05     Hs.368632   NM_000679   ADRA1B    Adrenergic, alpha-1B-, receptor 
A06     Hs.557     NM_000678   ADRA1D    Adrenergic, alpha-1D-, receptor 
A07     Hs.99913    NM_000684   ADRB1     Adrenergic, beta-1-, receptor 
A08     Hs.19383    NM_000029   AGT     Angiotensinogen  
A09     Hs.728754   NM_031850   AGTR1     Angiotensin II receptor, type 1 
A10     Hs.405348   NM_000686   AGTR2     Angiotensin II receptor, type 2 
A11     Hs.89499    NM_000698   ALOX5     Arachidonate 5-lipoxygenase 
A12     Hs.708024   NM_001172   ARG2     Arginase, type II 
B01     Hs.584884   NM_014382   ATP2C1     ATPase, Ca++ transport, type 2C, 1 
B02     Hs.495960   NM_005765   ATP6AP2    ATPase, H+ transporting, AP2 
B03     Hs.89648    NM_000490   AVP     Arginine vasopressin 
B04     Hs.2131     NM_000706   AVPR1A    Arginine vasopressin receptor 1A 
B05     Hs.1372     NM_000707   AVPR1B    Arginine vasopressin receptor 1B 
B06     Hs.525572   NM_000710   BDKRB1    Bradykinin receptor B1 
B07     Hs.654542   NM_000623   BDKRB2    Bradykinin receptor B2 
B08     Hs.471119   NM_001204   BMPR2     Bone morphogenic protein RII  
B09     Hs.118262   NM_000719   CACNA1C   Calcium voltage-dependent, L, α1C  
B10     Hs.37058    NM_001741   CALCA     Calcitonin-related polypeptide alpha 
B11     Hs.74034    NM_001753   CAV1     Caveolin 1, caveolae protein, 22kDa 
B12     Hs.434479   NM_000079   CHRNA1    Cholinergic receptor, nicotinic, α1  
C01     Hs.330386   NM_000747   CHRNB1    Cholinergic receptor, nicotinic, β 1  
C02     Hs.414565   NM_001288   CLIC1     Chloride intracellular channel 1 
C03     Hs.440544   NM_013943   CLIC4     Chloride intracellular channel 4 
C04     Hs.485489   NM_016929   CLIC5     Chloride intracellular channel 5 
C05     Hs.1323     NM_000087   CNGA1     Cyclic nucleotide gated channel α1 
C06     Hs.447360   NM_005140   CNGA2     Cyclic nucleotide gated channel α2 
C07     Hs.234785   NM_001298   CNGA3     Cyclic nucleotide gated channel α3 
C08     Hs.434618   NM_001037329   CNGA4     Cyclic nucleotide gated channel α 4 
C09     Hs.147062   NM_001297   CNGB1     Cyclic nucleotide gated channel β1 
C10     Hs.154433   NM_019098   CNGB3     Cyclic nucleotide gated channel β3 
C11     Hs.149252   NM_001875   CPS1     Carbamoyl-phosphate synthase 1,  
C12     Hs.121478   NM_000796   DRD3     Dopamine receptor D3 
D01     Hs.380681   NM_000798   DRD5     Dopamine receptor D5 
D02     Hs.195080   NM_001397   ECE1     Endothelin converting enzyme 1 
D03     Hs.511899   NM_001955   EDN1     Endothelin 1 
D04     Hs.1407     NM_001956   EDN2     Endothelin 2 
D05     Hs.183713   NM_001957   EDNRA     Endothelin receptor type A 
D06     Hs.82002    NM_000115   EDNRB     Endothelin receptor type B 
D07     Hs.212088   NM_001979   EPHX2     Epoxide hydrolase 2, cytoplasmic 
D08     Hs.86724    NM_000161   GCH1     GTP cyclohydrolase 1 
D09     Hs.631717   NM_005258   GCHFR     GTP cyclohydrolase I FR 
D10     Hs.24258    NM_000856   GUCY1A3   Guanylate cyclase 1, soluble, α3 
D11     Hs.77890    NM_000857   GUCY1B3   Guanylate cyclase 1, soluble, β3 
D12     Hs.597216   NM_001530   HIF1A    Hypoxia inducible factor 1, α subunit  
E01     Hs.567295   NM_002222   ITPR1     Inositol 1,4,5-trisphosphate receptor1 
E02     Hs.512235   NM_002223   ITPR2     Inositol 1,4,5-trisphosphate receptor2 
E03     Hs.102308   NM_004982   KCNJ8     Potassium inwardly-rectifying c J8 
E04     Hs.144795   NM_002247   KCNMA1   Potassium large conductance Ca
2+activated c  
E05     Hs.77741    NM_000893   KNG1     Kininogen 1 
E06     Hs.477375   NM_053025   MYLK     Myosin light chain kinase 
E07     Hs.86092    NM_033118   MYLK2     Myosin light chain kinase 2 
E08     Hs.130465   NM_182493   MYLK3     Myosin light chain kinase 3 
E09     Hs.707978   NM_000603   NOS3     Nitric oxide synthase 3  
E10     Hs.7236     NM_015953   NOSIP     NOS interacting protein 
E11     Hs.189780   NM_052946   NOSTRIN   Nitric oxide synthase trafficker 
E12     Hs.219140   NM_002521   NPPB     Natriuretic peptide B 
F01     Hs.247916   NM_024409   NPPC     Natriuretic peptide C 
F02     Hs.490330   NM_000906   NPR1    Natriuretic peptide receptor A  
F03     Hs.519057   NM_000909   NPY1R     Neuropeptide Y receptor Y1 
F04     Hs.321709   NM_002560   P2RX4     Purinergic receptor P2X, channel, 4 
F05     Hs.591150   NM_000921   PDE3A     Phosphodiesterase 3A, cGMP-i 
F06     Hs.445711   NM_000922   PDE3B     Phosphodiesterase 3B, cGMP-i 
F07     Hs.647971   NM_001083   PDE5A     Phosphodiesterase 5A, cGMP-s 
F08     Hs.268177   NM_002660   PLCG1     Phospholipase C, gamma 1 
  70 F09     Hs.413111   NM_002661   PLCG2     Phospholipase C, gamma 2  
F10     Hs.654556   NM_006258   PRKG1     Protein kinase, cGMP-dependent,I 
F11     Hs.570833   NM_006259   PRKG2     Protein kinase, cGMP-dependent,II 
F12     Hs.458324   NM_000960   PTGIR     Prostaglandin I2 receptor (IP) 
G01     Hs.201978   NM_000962   PTGS1    Prostaglandin-synthase 1 (COX1) 
G02     Hs.196384    NM_000963   PTGS2     Prostaglandin- synthase 2 (COX2) 
G03     Hs.3210     NM_000537   REN     Renin 
G04     Hs.154210   NM_001400   S1PR1     Sphingosine-1-phosphate receptor 1 
G05     Hs.591047   NM_001038   SCNN1A    Sodium channel, nonvolt-gated 1 α 
G06     Hs.414614   NM_000336   SCNN1B    Sodium channel, nonvolt-gated 1, β 
G07     Hs.371727   NM_001039   SCNN1G    Sodium channel, nonvolt-gated 1, γ 
G08     Hs.14846    NM_003045   SLC7A1     Solute carrier family 7  
G09    Hs.68061    NM_021972   SPHK1     Sphingosine kinase 1 
G10     Hs.528006   NM_020126   SPHK2     Sphingosine kinase 2 
G11     Hs.715862   NM_006786   UTS2     Urotensin 2 
G12     Hs.192720   NM_018949   UTS2R     Urotensin 2 receptor 
H01     Hs.520640   NM_001101   ACTB     Actin, beta 
H02     Hs.534255   NM_004048   B2M     Beta-2-microglobulin 
H03     Hs.592355   NM_002046   GAPDH     Glyceraldehyde-3-phosphate DH 
H04     Hs.412707   NM_000194   HPRT1     Hypoxan.phosphoribosyltransferas 1 
H05     Hs.546285   NM_001002   RPLP0     Ribosomal protein, large, P0 
H06     N/A     SA_00105   HGDC     Human Genomic DNA  
H07     N/A     SA_00104   RTC     Reverse Transcription Control 
H08     N/A     SA_00104   RTC     Reverse Transcription Control 
H09     N/A     SA_00104   RTC     Reverse Transcription Control 
H10     N/A     SA_00103   PPC     Positive PCR Control 
H11     N/A     SA_00103   PPC    Positive PCR Control 
H12     N/A     SA_00103   PPC     Positive PCR Control 
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Serum insulin and proinsulin levels were measured by specific insulin and proinsulin 
ELISA (Mercodia, Sweden). Insulin sensitivity was determined by the Homeostasis 
Model Assessment Index-Insulin Resistance (HOMA-IR). HOMA-IR was calculated 
by using the equation HOMA-IR= (insulin (mU/L) *  fasting glucose (mmol/l)) 
/22.5. Serum lipids profile was measured by conventional methods (COBAS, Roche, 
Switzerland). Adiponectin was measured in the serum, while TNF-α, IL-6 and leptin 
were measured in EDTA-plasma samples using commercially available 2-site 
ELISAs (R & D Systems, Oxon, UK). The IL-6 measures were carried out using the 
high sensitivity kit (R & D Systems, Oxon, UK).  In brief, samples and standards 
were pipetted into 96 wells of microplates precoated with specific antibody against 
the target protein. After a specified incubation period to allow ‘capturing’ of the 
target protein the unbound material was then washed away. A ‘detecting’ enzyme-
linked antibody specific for the target protein was then added and incubated. This 
was followed by washing to remove the unbound material. Then the substrate was 
added and the colour developed in proportion to the concentration of bound target 
protein. The reaction was stopped at set times as per manufactures instructions and 
the intensity of the colour measured on a microplate reader (TECAN, Infinite 2000) 
as absorbance at the specified wavelengths for each assay.    
2.5 Statistical Analysis: 
Myography data were recorded and analyzed using the Lab Chart software (DMT, 
Denmark). In response to each dose, peak values of vessel tension for contractile 
agent and lowest value for relaxing agents were  recorded; tension increase was 
calculated by peak value for each dose minus basal vessel tension (mN) divided by 
vessel diameter. Since it was difficult to obtain vessels from healthy lean people (as 
control) comparison was made between Ach and SNP responses in each segment to 
determine endothelial dysfunction. 
Data were analysed using SPSS version 15 for Windows (Statistical Package for the 
Social Sciences, SPSS UK Ltd, Chertsey, UK) and GraphPad Prism software version 
5.04 (GraphPad Inc. La Jolla, Ca USA). Normality of distributions was tested with 
  72 the Kolmogorov-Smirnov test. Data are shown as mean (±SEM or SD), or for non-
normally distributed data as median (interquartile range), in text and in tables. 
Agonist log –concentration response curves were constructed on log scale and data 
fitted using the sigmoidal fitting routine in Prism. The concentration of agonist 
causing 50% of maximum response is expressed as the mean log EC50 (pEC50), as 
measure of sensitivity to the agonist. Comparisons were made using student paired 
and unpaired t-tests or two way ANOVA as appropriate. Significance was defined as 
p<0.05. n= number of samples or experiments. 
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Chapter 3 
Depolarization & Noradrenaline mediated 
vasoconstriction 
 
 
 
 
 
 
 
 
 
  74 3.1 Introduction 
3.1.1 Regulation of arterial smooth muscle tone 
Arterial tone is the state of contraction of arteries which is a major determinant of 
peripheral vascular resistance and blood pressure. The contractile force of arterial 
smooth muscle is regulated by the intracellular concentration of Ca
2+ (204). This 
occurs by way of the dependence of myosin light chain phosphorylation on a kinase 
activated by the calcium/calmodulin complex. Then phosphorylation leads to actin-
myosin interaction and on to force development (205). Transient contractions of 
vascular  smooth muscle involve the  release  of Ca
2+  from  intracellular stores by 
inositol trisphosphate and/or by Ca
2+ itself (206). Thus maintained contraction (i.e., 
tone) depends on the long-term balance between the entry of external Ca
2+  (207) 
and its extrusion from the cell. Many pathways for membrane Ca
2+ entry involve 
voltage-dependent Ca channels (VDCCs), receptor-operated channels (ROCs), and 
Na
+-Ca
2+ exchange. Ca
2+ is extruded from smooth muscle by a plasma membrane 
adenosine triphosphatase (ATPase) and Na
+-Ca
2+ exchange (208).  
3.1.2 Role of Potassium channel  
Smooth muscles cells in arteries and arterioles have stable membrane potentials, 
which  measured in vivo are in the range of -40 to -55 mV (209), with resting 
potentials mainly permeable to K
+.  When subjected to physiological transmural 
pressures, they depolarize and develop tone (210). Sympathetic nerve stimulation 
depolarizes arteries and rarely causes action potential generation (210). Also, 
vasoconstrictors such as norepinephrine (NE) and serotonin appear to depolarize 
arterial smooth muscle (211). Vascular smooth muscle cell functions are regulated 
by membrane ion channels, mainly K
+  and Ca
2+  channels  (212). In general, K
+ 
channels regulate the membrane potential in these cells. Opening of K
+ channels 
increases K
+  efflux, which causes membrane hyperpolarization (the membrane 
potential becomes more negative as a result of loss of intracellular positive ions). 
This, in turn, closes the voltage sensitive L-type Ca
2+ channels. In contrast, closing 
of K
+  channels causes  membrane depolarization, opening of the L-type Ca
2+ 
channels, increase in the intracellular Ca
2+, and constriction. Thus, K
+ channels are 
  75 involved in the regulation of intracellular Ca
2+, in addition to playing a role in the 
smooth muscle cell excitability and arterial tone (213). 
In vascular smooth muscle cells there are four types of K
+ channels (213): (1) The 
delayed rectifier channel (KDR) opens with membrane depolarization, (2) The Ca
2+-
dependent K
+ channel (KCa) opens with membrane depolarization and with increases 
in the intracellular Ca2+. KCa plays an important role in the regulation of myogenic 
tone and it is a major target for cGMP that activates it. (3) The inward rectifier 
channel (Kir) is the least  studied channel  which  is opened by membrane 
hyperpolarization and, in contrast with the other K
+ channels, by increases in the 
extracellular K
+  and,  (4) The ATP-dependent channel  (KATP) opens when ADP 
levels rise and closes when ATP levels rise. Thus, KATP openers are vasodilators 
which  play an  important role in the control of basal tone and  autoregulation of 
several vascular beds and in metabolic regulation of blood flow (214). 
3.1.3 NA sympathetically mediated vasoconstriction 
The sympathetic nervous system controls the total peripheral vascular resistance and 
blood flow, by controlling the contraction of small arteries  (215). This control 
involves multiple neurotransmitters and receptors, as well as complex patterns of 
nerve fiber activity. There are 3 different sympathetic neurotransmitters:  ATP, 
noradrenaline  (NA), and neuropeptide Y (NPY),  which  are released from 
sympathetic varicosities, in which their effects vary with the pattern of nerve fiber 
activity  (216).  These neurotransmitters activate several cell signaling systems, 
including the ubiquitous intracellular Ca
2+  signaling systems (217).  The  3 
sympathetic co-transmitters, NA, ATP, and NPY contribute to sympathetically 
mediated vasoconstriction.   
NA binds to adrenoceptors. There are at least 9 subtypes of vascular adrenoceptors 
that have been identified: α1A, α 1B, α 1D, α 2A/D, α 2B, α 2C, β1, β2, and β3 
(218). α1A adrenoceptors are found in various vascular beds and are located post-
junctionally on vascular smooth muscle and have a primary role in controlling 
arterial tone, particularly in small resistance arteries (219). Endothelial cells have 5 
subtypes at least of adrenoceptors: α2A/D, α2C, β1, β2, and β3. Recently adrenergic 
  76 signaling mechanisms in arterial smooth muscle have been reviewed (220), with the 
emphasis on Ca
2+  activation of contraction and Ca
2+-sensitizing mechanisms 
activated by bath-applied phenylephrine. Sympathetic nerves in isolated blood vessel 
preparations can be selectively stimulated causing ATP and NA release. ATP is the 
predominant sympathetic effector in response to ‘single’ action potentials, while at 
high frequencies of activation, NA is the predominant sympathetic effector (221). 
The vasocontractile actions of ATP released from sympathetic nerves is mediated 
via P2X1 receptors  (222).  P2X receptors are  ionotropic receptors, and their 
activation by ATP leads to a rapid response involving calcium entry directly via P2X 
cation channels, membrane depolarization, and calcium influx through voltage-
activated calcium channels, while NA acts more slowly due to adrenoceptor 
coupling to G proteins and the involvement of second messengers. ATP and NA can 
act synergistically, resulting in a rapid onset augmented contraction (223).  
3.1.4 Sympathetic activation in obesity: 
In obesity there is over activity of the sympathetic nervous system due to overeating  
that leads to increased sympathetic outflow to the heart, kidneys, and vasculature, 
which may elevate BP (224),  and increase insulin secretion (225). 
Glucose utilization by skeletal  muscle  under the influence of insulin largely 
determines the process measured as insulin resistance, and is dictated by muscle 
blood flow  (226).  Therefore  the  reduction of  skeletal muscle blood flow in 
hypertension resulting from neural vasoconstriction could be the primary cause of 
the insulin resistance and the attendant hyperinsulinemia (226). Also sympathetic 
nervous activation can directly contribute to the lipid change which is part of the 
metabolic syndrome (227). Landsberg’s (225) explanation is that the sympathetic 
nervous activation of obesity might be  driven by high plasma levels of leptin. 
Leptin, a protein derived from adipose tissue,  has  an effect attributed to both 
suppression  of appetite and sympathetically mediated thermogenesis  (228). 
Experimentally,  rats  after  intravenous infusion of leptin,  show  activation of the 
sympathetic outflows to the kidneys and hindlimb vasculature, with no increase in 
heart rate, suggesting that the cardiac sympathetic nerves are not stimulated, these 
  77 effects have shown close parallels in the pattern of sympathetic nervous change seen 
in human obesity (229). 
Vascular function was assessed by wire myography. Cumulative concentration-
response curves were generated for various vasoconstrictors (e.g. noradrenaline, 
potassium chloride). 
3.2 Method 
3.2.1 Vascular reactivity: 
Obese patients who were undergoing laparoscopic bariatric surgery for weight loss 
were recruited and adipose tissue samples collected during surgery. Patients with 
serious illness were excluded such as coronary artery disease, malignancy and any 
other inflammatory conditions that might affect cytokine levels  as previously 
mentioned in section 2.1. Two AT samples was obtained during surgery from the 
abdominal subcutaneous and intra-abdominal omental depots and immediately 
transported in serum-free medium (Cellgro) to the lab. Arteries embedded in the 
tissues were then isolated and assessed for reactivity by wire myography. 
3.2.2 Myography protocol: 
Adipose tissues were dissected carefully under a dissecting microscope to isolate the 
vessels and differentiate artery from the vein.  The artery was cleaned and cut into 
segments (2 mm long), and mounted on wires in an isometric myograph containing 
NPSS. Vessels were continuously aerated at 37 C in PSS and pre-tensioned to an 
equivalent of 100 mmHg. The normalized luminal diameter of segments was 
obtained and equilibration period of at least 1 h was allowed during which time 
tissues were contracted with KCl (100 mM) and NA (10 µM) to optimize tissue 
response.  Following equilibration  period, vasoconstriction was assessed by 
constructing cumulative concentration-response curves for KCl (1 to100 mM) and 
NA  (10
–9  -  10
–4.5  M).  The dose–response curves were obtained in the same 
preparation separated by a washout period of 30–60 min. With this protocol, there 
was no apparent time-dependent change in the response to any of the 
  78 vasoconstrictors. Data were recorded with a Power Lab/LabChart data acquisition 
system (ADinstrment/Myotech, Denmark) as described previously in section 2.2. 
3.3 Results: 
3.3.1 Patient characteristics.  
Patients’ characteristics are shown in Table 2.  The MHO  and  PO patients were 
matched for BMI and did not differ in age or systemic blood pressure. The T2DM 
patients were marginally older. The plasma glucose levels were in the normal range 
in all groups. However, in order to maintain euglycaemia the PO and T2DM patients 
were hyperproinsulinaemic and hyperinsulinaemic compared to the MHO. The 
former two groups were also significantly insulin resistant compared to the MHO. 
However plasma leptin was released in PO vs MHO as well as in diabetic obese 
(DO) vs Non diabetic obese. There was no evidence of dyslipidaemia in the different 
groups. All other measured systemic markers were comparable.  
 
   
  79 Table 2: Patient characteristics for Vasoconstriction studies 
 
Data are shown as mean (SD) or median (interquartiles). * P˂0.05, ** P˂0.01, 
*** P˂0.001. 
   
Variables  MHO (n=6)  PO (n=22)  P 
MHO 
vs PO 
DO 
 (n=6) 
p 
DO.vs 
Nondiab. 
 
Age 
(years) 
28 (4.8)  33 (9.9)  0.28  40 (13)  0.05   
BMI 
(kg/m2) 
43 (5.15)  48 (22)  0.60  42 (6.8)  0.55   
SBP 
(mmHg) 
120 (13)  127 (16.5)  0.34  129 (7.9)  0.60   
DBP 
(mmHg) 
70 (8.3)  73 (9.4)  0.53  75 (5.7)  0.46   
MAP 
(mmHg) 
87 (9.3)  86.3 (22)  0.97  93 (5.7)  0.43   
Proinsulin 
(miU/ml) 
1.5 (1.2-2.5)  2.81 (1.6-15.4)  0.06  9.5 (6.6-29)  0.01   
FBG 
(mmol/L) 
4.8 (1.02)  5.8 (1.3)  0.10  8.32 (4.26)  0.17   
Insulin 
(miU/ml) 
7.1 (5.6-8.3)  15.1 (11-19.3)  0.001  16 (10-162)  0.47   
HOMA  1.4 (0.9-1.6)  3.9 (2.7-4.7)  0.001  4.0 (3-103)  0.26   
HDL 
(mmol/L) 
1.4 (0.44)  0.90 (0.33)  0.01  0.8 (0.225)  0.21   
LDL 
(mmol/L) 
2.6 (0.8)  2.3 (0.78)  0.31  2 (0.5)  0.30   
TG 
(mmol/L) 
0.83 (0.7-0.9)  0.9 (0.63-1.4)  0.52  1.4 (0.83-3)  0.08   
Cholesterol 
(mmol/L) 
4.4 (0.9)  3.6 (1.09)  0.10  3.5 (0.9)  0.56   
IL6  
(pg/ml) 
4.1 (1.7)  4.26 (2.3)  0.85  4.1 (2.1)  0.91   
MCP-1 
(pg/ml) 
224.8 (175.8-352.1)  166 (160-276.6)  0.34  338.44  0.23   
Leptin 
(ng/mL) 
93.7 (21.6)  65.5 (32)  0.05  38 (31.1)  0.03   
VEGF 
(pg/mL) 
64 (50)  101.4 (64)  0.34  102.9     
Adiponectin 
(µg/mL) 
3.01 (1.05)  3.54 (2.2)  0.62  6.81     
  80 3.3.2 Responses to vasoconstrictors 
To test the contractile properties of the adipose microvessels, two vasoconstrictors 
with  different mechanisms of action were  applied. Cumulative concentration-
response curves were constructed for KCl (depolarizandtion dependent constrictor) 
and NA (sympathomimetic and α- adrenergic receptor agonist) on both SC and OM 
vessels. For comparison between SC and OM only data from the same patients were 
considered. Tension recorded in each vessel was also normalized to vessel size to 
reduce the impact of size.  
KCl, like NA, produced concentration-dependent contractions of both SC and OM 
vessels. A typical recording of force changes over time in response to cumulative 
addition of NA is shown in (Figure 13). 
 
 
 
Figure 13: Typical tracing of contractile responses of a vessel segment (sub-
cutaneous micro vessel) to increasing concentrations of NA (10
-9-10
-4.5M). 
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  81 3.3.2.1 KCl contraction 
3.3.2.1.1: Impact of adipose depot   
To determine the impact of adipose depots on the contractile response to KCl, data 
obtained from same patients were used. Generally, OM vessels generated greater 
maximum force to KCl compared with SC vessels. However, when separated into 
the 3 metabolic groups of MHO (Fig 14), PO (Fig 15) and diabetic obese (DO, Fig 
16), significantly greater maximum force was only recorded in OM vessels from PO 
group compared to SC from same patients (Emax 0.028±0.005 vs 0.019±0.003 
mN/µm for OM vs SC respectively, p˂0.05). Comparable maximum forces were 
recorded MHO (Emax 0.021±0.006 vs 0.017±0.004 for OM vs SC, p= 0.4595) and 
DO (0.028±0.004 vs 0.022±0.007 for OM vs SC p= 0.5655) groups. In the same 
vein, there were no differences in the sensitivities of both vessel types from any of 
the metabolic groups, to KCl.  
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Figure 14:  KCl contractions of SC and OM vessels obtained from same MHO 
individuals. Contractions by both vessel types were comparable at all KCl 
concentrations. Data points are Mean ± SEM of n=4. 
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Figure 15: KCl contractions of SC and OM vessels obtained from same PO 
individuals.  OM vessels developed greater force compared to SC vessels with 
increasing KCl concentrations  (≥40  mM).  The  left  ward  shift  of  OM  curve  was 
significant (p˂0.05). Data points are Mean ± SEM of n=8. 
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Figure 16:  KCl contractions of SC and OM vessels obtained from same DO 
individuals.  OM vessels developed greater force compared to SC vessels with 
increasing KCl concentrations (≥40 mM), although the curves were not statistically 
different. Data points are Mean ± SEM of n=4. 
 
 
 
  85 3.3.2.1.2: Impact of metabolic status and diabetes   
To determine the impact of patients’ metabolic status and of diabetes on the 
contractile response to KCl, data obtained from all OM and SC vessels from all 
patients were used. The SC vessel curves for the 3 metabolic groups of MHO, PO 
and  DO  were comparable (Fig  17  A).  The Emax values (0.022±0.007 vs 
0.019±0.003 vs 0.017±0.004 mN/µm for diabetic vs PO vs MHO) and sensitivities 
to KCl (EC50 34.22±4.42 vs 30.05±3.64 vs 29.52±2.60 mM for diabetic vs PO vs 
MHO) of the SC vessels from the 3 groups were also similar. In contrast, the OM 
vessel curves for the 3 metabolic groups were different (p˂0.05). In particular, the 
OM curve for the DO  group  was significantly shifted to the left of both MHO 
(p˂0.01)  and  PO  (p˂0.05)  groups  (17  B). Although the OM curve for PO lies 
slightly to the left of the MHO curve, the two were not statistically different. In the 
same vein, the Emax values for MHO (0.019±0.004  mN/µm), PO (0.022±0.003 
mN/µm) and DO (0.028±0.004 mN/µm) OM vessels were not statistically different. 
Similarly, the EC50 values of 31.95±1.37, 30.36±1.48 and 30.14±2.59 mM for OM 
vessels from MHO, PO and DO groups respectively were also not different. 
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Figure 17A: Summary of the impact of metabolic status and diabetes on KCl 
contraction of SC from all patients studied. The curves for the 3 metabolic groups 
were comparable. Data are Mean ± SEM of n=4-15. 
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Figure 17B: Summary of the impact of metabolic status and diabetes on KCl 
contraction of OM vessels from all patients studied. The curve for the DO group 
was shifted to the left of the curves for both MHO and PO groups. The curves for 
MHO vs PO were comparable. Data are Mean ± SEM of n=4-15. 
  88 3.3.2.2 Noradrenaline (NA) Contractions 
3.3.2.2.1: Impact of adipose depot   
To determine the impact of adipose depots on the contractile response to NA, data 
obtained from same patients were used.  For the MHO, comparable curves were 
generated for SC and OM vessels (Emax 0.028±0.006 vs 0.017±0.004 for OM vs 
SC, p= 0.418, Fig 18). For the PO group, the SC vessels were significantly more 
sensitive to NA compared with OM vessels (pEC50 =  7.08±0.002  for SC vs 
6.29±0.158 for OM, p˂0.001). Although maximum contraction was slightly greater 
in OM compared with SC vessels, the difference was not statistically significant 
(Emax 0.032±0.002 vs 0.027±0.002 mN/µm for OM vs SC respectively, p=0.097, 
Fig 19). The data for the DO group followed the pattern for the PO group: The curve 
for SC vessels was shifted to the left of the curve for OM vessels (p˂0.05, Fig 20), 
with pEC50 values of 7.147±0.162  vs  6.429±0.157 respectively (p˂0.05), 
representing greater sensitivity of the SC vessels to NA. However, there was no 
difference in the maximum contractions of both vessels (Emax values 0.036±0.005 
vs 0.042±0.008 for OM vs SC p= 0.3105).  
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Figure 18: NA contractions of SC and OM vessels obtained from same MHO 
individuals.  Contractions by both vessel types were comparable at all  NA 
concentrations. Data points are Mean ± SEM of n=5. 
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Figure 19:  NA contractions of SC and OM vessels obtained from same PO 
individuals. First half of the curve for SC vessels was shifted to the left of the OM 
curve (reflecting greater sensitivity to NA compared with the OM vessels, p˂0.001). 
Although maximum contractions were slightly higher in the OM compared to SC 
vessels, the differences were not significant. Data points are Mean ± SEM of n=13. 
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Figure 2018:  NA contractions of SC and OM vessels obtained from same DO 
individuals.  The curve for SC vessels was shifted to the left of the OM curve 
(reflecting  greater  sensitivity  to  NA  compared  with  the  OM  vessels,  p˂0.05). 
However, maximum contractions for both vessel types were comparable. Data points 
are Mean ± SEM of n=3. 
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To determine the impact of patients’ metabolic status and of diabetes on the 
contractile response to NA, data obtained from all OM and SC vessels from all 
patients were used. Whereas, the SC curves for the 3 metabolic groups (MHO, PO 
and  DO)  were different (p˂0.0001, Fig 21A), the OM curves were statistically 
similar (Fig 21 B). In particular, the SC curve for the DO group was significantly 
shifted to the left of the SC curves for both  MHO (p˂0.001) and PO (p˂0.001) 
groups. Similarly, the SC vessels from DO were more sensitive to NA compared 
with SC vessels from MHO (pEC50 = 7.148±0.162 vs 6.648±0.044, p˂0.01) but not 
with SC vessels from PO (pEC50 = 7.048±0.156). The SC curves for MHO and PO 
groups  were not statistically different. In the same vein, the maximum NA 
contraction of the SC vessels from the 3 groups were not statistically different 
(Emax = 0.042±0.008, 0.022±0.003 and 0.027±0.003 mN/µm for DO, PO and MHO 
respectively).  
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 Figure 21A: Summary of the impact of metabolic status and diabetes on NA 
contraction of SC vessels from all patients studied. The curve for the DO group 
was shifted to the left of the curves for both MHO and PO groups. The DO was 
more sensitivity to NA compared with MHO (p˂0.01) but not with PO. Data are 
Mean ± SEM of n=3-16. 
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 Figure 21B: Summary of the impact of metabolic status and diabetes on NA 
contraction of OM vessels from all patients studied. The curves from the 3 
metabolic groups were comparable. Data are Mean ± SEM of n=3-16. 
 
 
 
 
  95 3.4 Discussion: 
The results show that depolarization-induced (KCl) contractions of the more visceral 
OM vessels were generally more powerful compared with SC vessels from same 
patients. This was particularly so with the pathologically obese group. This suggests 
either greater amounts of contractile proteins or greater ability to maximally activate 
these proteins in these vessels. The former appears unlikely since the force generated 
by each vessel segment was normalized to size. More so, the mRNA expression 
arrays show no difference in the expression of α actin between the vessel types. 
Although the sensitivities of the 3 OM vessel groups to KCl were not statistically 
different, differences in their sensitivities to cytosolic calcium (Ca
2+ sensitization) 
cannot be ruled out. Variation in local release of adipokines can indeed affect the 
later (165). This is consistent with the metabolic status of the patients having an 
effect  on  the OM KCl response with the  PO and DO  groups  showing greater 
maximum force compared with the MHO group. 
 
Noradrenergic activation also produced dose-dependent contractions of both SC and 
OM vessels from all patients. With respect to depot effect, SC vessels from PO and 
diabetic displayed greater sensitivity to NA compared to OM vessels. This is 
probably a reflection of differences in α1-adrenergic receptor populations of these 
vessels. The α1A receptor primarily controls the tone of small resistance arteries 
(201). It is however possible that other adrenoceptors present in both endothelium 
and vascular smooth muscle (217)  of the 2 vessel preparations could have also 
influenced the sensitivity to NA.  
The maximum NA contraction of all 3 SC and OM vessel groups was comparable, 
suggesting comparable calcium mobilization mechanisms and activation of the 
contractile proteins. When separated into the 3 metabolic groups, the impact of the 
metabolic status of the patients on their response to NA was much more pronounced 
in the SC vessels. The order of sensitivities to NA were DO > PO > MHO. This 
again may be explained by the impact of the metabolic changes in the SC depots on 
α1 adrenoceptor expression. 
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Chapter 4 
Endothelium-dependent and independent vasorelaxation 
 
 
 
 
 
 
 
 
 
   
  97 4.1 Introduction 
4.1.1 Endothelial dysfunction in obesity:  
Endothelial dysfunction  is a condition characterized by an impairment of 
endothelium-dependent relaxation (for instance, to acetylcholine) caused by a loss of 
NO bioactivity in the vessel wall which contributes to several pathological 
conditions (230). Increased pro-oxidant cell activity (oxidative stress), reduced 
expression/activity of eNOS, or unbalanced production/release of vasoconstrictor 
mediators are among mechanisms responsible for impaired NO availability (117). 
Besides impairment in NO bioavailability endothelial dysfunction is characterized 
by an enhanced bioactivity of vasoconstrictor and proatherogenic factors. ET-1, the 
most potent vasoconstrictor peptide synthesized by the endothelial cells, appears to 
play a central role in the pathophysiology of the vasomotor abnormalities associated 
with endothelial dysfunction and in the formation and progression of the 
atherosclerotic plaque (231). Increased production or activity of other 
vasoconstrictor substances, such as angiotensin II (Ang II), is also implicated in 
endothelial dysfunction in obesity and hypertension (232). In addition thromboxane 
A2 and prostaglandin H2 (TXA2/PGH2) receptor expression is enhanced in obesity-
associated hypertension (233). This alteration suggests on association with increased 
conversion of arachidonic acid to prostaglandins by cyclooxygenase-2 (COX2), an 
isoform of COX described generally to be induced specifically under inflammatory 
conditions (234), though may be constitutively expressed in adipose tissue (235).   
Endothelial dysfunction, secondary to impaired nitric oxide (NO) availability due to 
increased reactive oxygen species (ROS) generation, is a common alteration of the 
major cardiovascular risk factors (236). TNF-α is involved in reducing vascular NO 
availability; this action is exerted both indirectly, by induction of ROS generation 
via nicotinamide adenine dinucleotide phosphate (NAD[P]H) oxidase or inducible 
nitric oxide synthase (iNOS) activation, and by direct inhibition of endothelial nitric 
oxide synthase (eNOS) activity (237).  
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4.1.2 Obesity and endothelial dysfunction:  
In obesity endothelial dysfunction is known as an important factor in the 
pathogenesis of vascular disease. AT is  an important modulator of endothelial 
function via secretion of a variety of hormones, including adiponectin, leptin, 
resistin, PAI-1,  angiotensin,  estradiol,  and  the  cytokines  TNFα  and  IL-6 (238).   
Obesity independently has been associated with a condition of chronic inflammation 
secondary to an abnormal production of pro-inflammatory mediators, in particular 
TNF-α that might negatively influence vascular reactivity (239). Moreover, the local 
inflammation of perivascular fat might exert a detrimental action on the vascular 
tone of adjacent small vessels in obese patients (175). A study showed that small 
resistance arteries, isolated from visceral adipose tissue from severely obese patients 
are characterized by a marked endothelial dysfunction caused by reduced NO 
availability. This result was attributed to an increased vascular production and 
biological activity of TNF-α that promotes superoxide generation via both NAD(P)H 
oxidase and iNOS activation. Thus, obesity is an inflammatory condition, in which 
small vessels of visceral fat are important sources of low-grade inflammation and 
oxidative stress that together with the perivascular adipose tissue  could directly 
contribute to the local development of insulin resistance (240). 
The responses to vasodilators (e.g. acetylcholine, Sodium nitroprusside (SNP), and 
prostaglandin E2) were ascertained. 
4.2 Method: 
The general protocol for wire myography described in 3.2 was used. Adipose tissues 
were dissected under a dissecting microscope to isolate the vessels and differentiate 
artery from the vein.  The cleaned artery was cut into segments (2 mm long), and 
mounted on wires in an isometric myograph containing normal PSS. Vessels were 
continuously aerated at 37 C in PSS and pre-tensioned to an equivalent of 100 
mmHg. The normalized luminal diameter of segments was obtained and 
equilibration period of at least 1 h was allowed during which time tissues were 
  99 contracted with KCl (90 mM) and NA (10 µM) to test viability and optimize tissue 
response.  
Endothelial function was assessed by measurement of relaxation to acetylcholine. 
Cumulative concentration-response curves were constructed for acetylcholine on 
initial tone built with 1-5 µM NA. Curves were also generated for sodium 
nitroprusside to measure the responsiveness of segments to direct NO application. 
To test for relaxation to other endogenous dilators, curves were constructed for 
prostaglandin E2. The magnitude of drop in tone due to each dose of agonist was 
expressed as percentage relaxation of the initial tone.   
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4.3.1 Table 3: Patient characteristics for Vasodilatation studies. 
 
Data are shown as mean (SD) or median (interquartiles). * P˂0.05, ** P˂0.01, 
*** P˂0.001. 
Variables  MHO (n=5)  PO 
(n=19) 
P 
MHO vs 
PO 
DO 
 (n=5) 
P 
DO vs 
Nondiab 
Age  
(years) 
38 (6.1)  31 (8.3)  0.11  38 (11.9)  0.25 
BMI 
(kg/m2) 
42 (5.9)  48 (23)  0.57  43 (7.3)  0.67 
SBP 
(mmHg) 
116 (11)  129 (16.2)  0.11  129 (8.8)  0.72 
DBP 
(mmHg) 
67 (11)  73 (10.6)  0.26  74 (5.7)  0.71 
MAP 
(mmHg) 
83.5 (8.2)  92 (11.7)  0.15  92 (6)  0.56 
Proinsulin 
(miU/ml) 
1.8 (0.9-3.03)  3.6 (1.6-10.4)  0.05  8.73 (5.9-22.3)  0.07 
FBG 
(mmol/L) 
5.6 (1.1)  6.1 (1.34)  0.44  9.1 (4.3)  0.19 
Insulin 
(miU/ml) 
5.6 (3.3-6.1)  15.1 (12-22)  0.002  17.6 (8.5-17.6)  0.35 
HOMA  1.2 (0.3-1.8)  3.52 (2.3-6)  0.02  3.8 (2.6-3.8)  0.27 
HDL 
(mmol/L) 
1.5 (0.5)  1.12 (0.30)  0.07  1.04 (0.41)  0.43 
LDL 
(mmol/L) 
2.84 (0.55)  2.7 (1.1)  0.78  2.3 (0.62)  0.36 
TG 
(mmol/L) 
0.9 (0.6-2.1)  0.94 (0.7-1.5)  0.68  1.43 (1.1-3.4)  0.08 
Cholesterol 
(mmol/L) 
5.5 (0.7)  4.62 (1.3)  0.59  4.14 (0.8)  0.36 
IL6  
(pg/ml) 
3.8 (1.8)  4.4 (2.2)  0.55  4.73 (2)  0.69 
MCP-1 
(pg/ml) 
223.3 (160-500)  176.3 (160-342)  0.46  338.44  0.53 
Leptin 
(ng/mL) 
57 (25.04)  59.5 (30.9)  0.84  34.63 (35)  0.15 
VEGF 
(pg/mL) 
78.5 (36.3)  147.7 (78.2)  0.14  102.89  0.85 
Adiponectin 
(µg/mL) 
4.2 (2.3)  3.3 (1.84)  0.47     
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4.3.2 Responses to vasodilators 
4.3.2.1 Relaxations to Ach: 
Ach produced concentration-dependent relaxation of both SC and OM vessels (A 
typical tracing is shown in figure 22.  
 
 
 
 
Figure 22:  A typical relaxation response of a sub-cutaneous micro vessel to 
Acetylcholine. The vessel tone decreased with increasing doses of Ach (10
-9-10
-
4.5M).  
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  102 4.3.2.2 Ach relaxation 
4.3.2.2.1 Impact of adipose depot:   
To determine the impact of adipose depots Ach relaxation was recorded in both SC 
and OM vessels from the same patients. Generally, both vessel types responded 
dose-dependently to Ach. The OM and SC curves for MHO (n=3, Fig 23) and DO 
(n=4, Fig 24) groups did not show any depot- specific differences. The Imax values 
for OM vs SC vessels for MHO were 72.03±13.99 vs 77.113±3.922 % and for DO 
group were 71.95±12.72 vs 68.01± 15.18).  In contrast, the curve for OM vessels 
from the PO group was significantly shifted to the right compared with the curve for 
SC vessels from same patients (p < 0.01, Fig 25). The Imax values were 64.978± 
6.69 vs 80.74±4.66 mN/µm for OM vs SC vessels (p= 0.067). Both vessels from 
each of the 3 groups were equally sensitive. For the MHO group the pIC50 values 
were 6.804±0.888 vs 6.913±0.121 for OM vs SC vessels respectively. For the PO 
group the pIC50 values were 5.701±1.289 vs 7.032±0.140 and for the DO group 
6.841± 0.376 vs 7.178± 0.067 for OM vs SC vessels respectively.  
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Figure 23: Ach relaxations of SC and OM vessels obtained from same MHO 
individuals.  Relaxations by both vessel types were comparable at all Ach 
concentrations. Data points are Mean ± SEM of n=3. 
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Figure  24:  Ach  relaxations of SC and OM vessels obtained from same DO 
individuals.  Relaxations by both vessel types were comparable at all Ach 
concentrations. Data points are Mean ± SEM of n=4. 
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Figure  25:  Ach relaxations of SC and OM vessels obtained from same PO 
individuals. Relaxation was attenuated in OM vessels compared to SC vessels with 
increasing Ach concentrations. The right ward shift of OM curve was significant 
(p˂0.01). Data points are Mean ± SEM of n=11. 
 
   
  106 4.3.2.2.2 Impact of metabolic status and diabetes   
To determine the impact of patients’ metabolic status and of diabetes on the 
relaxation response to Ach, data obtained from all OM and SC vessels from all 
patients were used. The 3 SC curves for the 3 metabolic groups were not statistically 
different (Fig 26A); Their Imax values were 74.14±4.06  vs  82.57±2.68  vs 
68.01±15.18 % for MHO vs PO vs DO respectively. Similarly, their pIC50 values 
were 7.11±0.216  vs 6.96±0.094  vs 7.18±0.067  mM for MHO vs PO vs  diabetic 
respectively. In contrast, the Ach curves for OM vessels from the 3 metabolic groups 
were  different  (p˂0.001).  In  particular,  the  curves  for  OM  vessels  from  the  DO 
(p˂0.01) and PO (p˂0.0001) groups were significantly shifted to the right of the 
curve for the MHO group (Fig 26B). The OM curves for DO and PO groups were 
comparable. The Imax values for OM vessels from DO, PO and MHO groups were 
71.21 ±9.88, 64.06±3.84 and 80.21±6.58 % respectively, and the pIC50 values for 
these vessels were 6.845 ± 0.029, 7.163±0.266 and 7.167± 0.441 respectively. When 
values were compared between groups, only the Imax values for PO vs MHO were 
statistically different (p˂0.05). 
 
SNP is a direct donor of NO and dilates blood vessels independent of the 
endothelium. For this reason it was used as a control for Ach release of NO from the 
endothelium. Overall SNP produced greater relaxation of OM vessels compared 
with SC vessels (p˂0.05, Fig 27). When SNP and Ach curves were compared for 
each vessel type, SNP curve was significantly shifted to the left of the Ach curve for 
OM vessels (p˂0.01, Fig 28 A), with pIC50 values of 7.072± 0.312 for SNP vs 
7.829±.847  for  Ach (p=0.8795)  and,  maximum response of OM  vessels to both 
drugs  were higher for SNP vs Ach (Imax = 93.068±2.77 vs 55.19±7.716).  In 
contrast, the positions of the curves were reversed for SC vessels with SNP curve on 
the right of the Ach curve (p=0.0002, Fig 28 B) and pIC50 values of 6.107±0.294 vs 
6.88±0.194 for SNP vs Ach respectively (p=0.0579).  Again, the Imax values 
(90.762±5.131 vs 87.586±2.537 for SNP vs Ach) for these vessels in response to the 
2 drugs were comparable. 
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Figure 26A:  Summary of the impact of metabolic status and diabetes on Ach 
relaxation of SC vessels from all patients studied. The curves from the 3 
metabolic groups were comparable. Data are Mean ± SEM of n=4-21. 
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Figure 26B:  Summary of the impact of metabolic status and diabetes on Ach 
relaxation of OM vessels from all patients studied. The curve for the PO was 
shifted to the right of the curves for both MHO ((p˂0.0001) and DO (p˂0.01). Data 
are Mean ± SEM of n=5-21. 
 
 
 
 
 
  109 4.3.2.3 Relaxation to SNP:  
 
-10 -8 -6 -4
0
20
40
60
80
100
SNP (log M)
R
e
l
a
x
a
t
i
o
n
 
%
SC (n=3)
OM (n=3)
SNP
 
Figure  27:  SNP relaxations of SC and OM vessels obtained from same 
individuals. The SC curve was shifted to the right of the OM curve (p˂0.05). The 
Imax and IC50 were comparable. Data points are Mean ± SEM of n=3. 
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Figure 28A: Comparison between SNP and Ach relaxation of OM vessels. The 
relaxation to Ach was significantly attenuated (with significant rightward shift) 
compared with SNP (p< 0.0001). Data points are Mean ± SEM of n= 5. 
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Figure 28B: Comparison between SNP and Ach relaxation of SC vessels. The 
relaxation curve for Ach was slightly shifted to the left of the SNP curve. The 
maximum responses to both drugs were comparable. Data points are Mean ± SEM 
of n= 5. 
  
 
 
 
 
  112 4.3.2.4 Relaxation to PGE2: 
PGE2 like SNP, but unlike, Ach produced greater relaxation in OM compared with 
SC vessels, with SC to the right of OM curve (p˂0.05, Fig 29). However, Imax was 
84.48±6.75 for OM vs 65.99±13.55 for SC (p= 0. 2677). There was no difference in 
sensitivity between SC and OM (pIC50 values were -6.34± 0.22 vs -7.06±0.45 for 
SC vs OM respectively (p= 0.2094). 
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Figure  29:  PGE2 relaxations of SC and OM vessels obtained from same 
individuals.  PGE2 produced greater relaxation of OM compared with SC vessels 
(p= 0.39) with increasing PGE2 concentrations. Data points are Mean ± SEM of 
n=4. 
 
 
  113 4.4 Discussion 
The data clearly demonstrate endothelial dysfunction in OM, but not in SC, vessels 
from PO and DO groups.  SC vessels from the 3 metabolic groups appeared to have 
apparently  normal and similar endothelium-dependent  dilator  profile. The depot 
specific  differences in endothelial function of these  vessels suggest differential 
impact of local adipose tissue environment on these vessels. This is consistent with 
the reported more pathogenic milieu of the OM  compared with the SC adipose 
tissues (81, 82). The SC & OM show functional differences in the expression of 
genes, especially those regulating inflammation and vascular function, presence of 
complement factors and fatty acid binding protein that are all expressed at higher 
levels in OM than in SC fat (85, 86). Expansion of these depots might happen via 
adipocyte hypertrophy and/or hyperplasia that accumulate of excess fat in the 
visceral compartment, while subcutaneous fat mass remain normal, carries the 
greater metabolic risk (77).   
Even though the numbers for the DO  group was low, the data showed a trend 
consistent with reported vascular impact of the disease (160).  Type 2 diabetes is 
characterized by insulin resistance which is associated with elevations in free fatty 
acid levels (165)  and endothelial dysfunction.  Abdominal adipose tissue  is 
particularly dysfunctional, in type 2 diabetes, is more insulin resistant and releases 
more free fatty acids compared with the type of adipose in other locations (155). 
Diabetes also induces PKC activity, NF-κβ production, and generation of oxygen-
derived free radicals in VSMC, similar to these effects in endothelial cells that might 
contribute to endothelial dysfunction.    
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Chapter 5 
Mechanisms of endothelial function and dysfunction 
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5.1.1 Role of Nitric oxide (NO) 
Nitric oxide is generated from L-arginine by the action of endothelial nitric oxide 
synthase in the presence of cofactors, such as tetrahydrobiopterin. When NO is 
produced, it diffuses to vascular smooth muscle cells and activates guanylate 
cyclase, which leads to cGMP-mediated vasodilatation (241). Also NO is involved 
in several protective functions of the endothelium by limiting vascular inflammation, 
vascular smooth muscle proliferation, platelet aggregation, and production of tissue 
factors (242).  So, modifications of normal endothelial physiology result in 
endothelial dysfunction that is characterized by decrease in the bioavailability of 
vasodilators, especially NO (243).  
Endothelium functionally regulates vascular homeostasis by elaborating a number of 
paracrine factors responsible for maintaining normal vascular tone, and blood 
fluidity, and limiting vascular inflammation and smooth muscle cell proliferation 
(244, 245). Therefore endothelial dysfunction is a systemic pathological state of the 
endothelium, in which there is a reduction in the bioavailability of vasodilators, 
especially nitric oxide, leading to impaired endothelium-dependent vasodilation, as 
well as disarrangement in vascular wall metabolism and function. Also, another key 
factor in endothelial dysfunction is overproduction of reactive oxygen species which 
has been implicated in the development of hypertension, atherosclerosis, diabetes, 
cardiac hypertrophy, heart failure, ischemia-reperfusion injury, and stroke. Thus 
impaired endothelial activity is believed to have a major causal role in the 
pathophysiology of vascular disease, hypertension, and heart failure (246). 
NO can hyperpolarize, or repolarize vascular smooth muscle cells by activating, in 
either a cyclic-GMP–dependent or cyclic-GMP–independent manner, potassium 
channels like KATP, BKCa, Kir, and/or KV. NO interactions with other ionic channels 
of the smooth muscle, including chloride and cationic channels, also influences the 
membrane potential of the smooth muscle cells indirectly in an autocrine fashion 
(247). Inhibitions of NO synthesis do not necessarily fully inhibit the production of 
NO, thus residual NO can be produced by the endothelial cells and contribute to the 
  116 relaxation and/or hyperpolarization of the underlying vascular smooth muscle. NO 
can also contribute in another way to responses resistant to inhibitors of 
cyclooxygenases and NO synthases, because NO can be stored and released 
independently of the activation of NO synthase. Two such stores have been 
described, the first store is the so-called photosensitive store that involves the release 
of NO by ultraviolet light and the second one is located in the adventitia and 
generated by the formation of protein-bound dinitrosyl non-heme iron complexes 
and S-nitrosated proteins (248). Therefore, low-molecular-weight thiols displace NO 
from these stores and transfer it to various target membrane proteins including 
potassium channels and may therefore function as hyperpolarizing factors (249). 
5.1.2 Role of Cyclooxygenase (COX) 
Cyclooxygenase (COX) is the key enzyme required for the conversion of 
arachidonic acid to prostaglandins (PG) G2 and PGH2. PGH2 subsequently converts 
to a variety of prostanoids  that  constitute  PGE2,  PGD2,  PGF2α,  PGI2,  and 
thromboxane (TX) A2  which interact with prostanoid (P) receptors.  Prostanoid 
receptors  belong to the G-protein-coupled seven transmembrane domains family, 
and are classified into five subtypes (DP, EP, FP, IP and TP receptors) as a function 
of their preferential affinity towards those PGs (250). The array of PGs produced 
varies according to the downstream enzymatic machinery present in each cell type 
(251). Prostanoids are involved in control of human vascular tone (252) and 
remodeling the vascular wall as well as in platelet aggregation and thrombosis 
(253,254).  Prostaglandin  F2α  (PGF2α)  and  thromboxane  A2  (TXA2)  induce 
vasoconstriction, prostaglandin D2 (PGD2) and prostacyclin (PGI2) cause 
vasodilatation, while prostaglandin E2 (PGE2) may produce both effects depending 
on the receptors. PGE2 may activate 4 receptor subtypes (EP1, EP2, EP3 and EP4). 
Once they are expressed in smooth muscle cells; EP1or EP3 receptors are associated 
with vasoconstriction, whereas the activation of EP2 or EP4 receptors is associated 
with vasorelaxation (255). 
Two cyclooxygenase isoforms have been identified known as COX-1 and COX-2 
encoded by two different genes. Under many circumstances the COX-1 enzyme is 
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mediated by COX-1 (e.g. in gastric mucosa) whereas COX-2 is inducible (e.g. at 
sites of inflammation). The functional role for each isoform is consistent according 
to their tissue expression patterns, although nearly all normal tissues express COX-1 
with low to undetectable levels of COX-2. Other differences between COX-1 and 
COX-2 include differences in utilization of arachidonic acid substrate pools as well 
as in mRNA stability (256). In healthy blood vessels (both endothelial and, to a 
lesser extent, vascular smooth muscle cells) express the two COXs, COX-1 being 
the predominant isoform (257), however, COX-2 appears to be the major contributor 
of the overall systemic generation of prostacyclin, in endothelial cells of both 
healthy and diseased blood vessels, while COX-1 is also an important source of PGs 
(258,259). 
5.1.2.1 COX-1: has been found in nearly all tissues under basal conditions (260) and 
the major function for COX-1’s is to provide PG precursors for homeostatic 
regulation. The important site of COX-1 function is the blood platelet, where the 
enzyme is responsible for providing precursors for thromboxane synthesis (261). 
While, in the adjacent vascular endothelium PGs play a different role to release 
eicosanoids by activated platelets to provide both a substrate and stimulus for the 
generation of prostacyclin (PGI2) by the endothelium. The latter compound 
stimulates vasodilatation, counteracting the vasoconstrictor, thromboxane.  Thus, 
COX-1 appears to function in two physiological systems leading to vasodilatation in 
the presence of contractile conditions (262). 
5.1.2.2 COX-2:  is mainly an inflammatory, inducible enzyme, and is the major 
generator of the vasodilator PGI2, which functions especially when NO 
bioavailability is diminished. Endothelial dysfunction is reversed by a 
complementary up regulation of COX-2 expression and activity as shown in the 
mesenteric vascular bed of mice with streptozotocin-induced diabetes (263), 
whereas attenuated NO-dependent vasodilatations in diabetic patients may be 
compensated for by the emerging vasodilator effect of prostacyclin (264). Compared 
with patients, non-documented as diabetic, coronary arterioles from diabetic patients 
  118 show a significant up-regulation of COX-2 expression, that contributes to enhance 
bradykinin-induced vasodilatations (265). The availability of selective COX-2 
inhibitors now allows a more in-depth investigation on the emerging role of COX-2 
as an inflammatory mediator releasing vasoconstrictors in morbidly obese. 
COX is also involved in the endothelial generation of reactive oxygen species, 
which is a key factor in the generation of endothelium-dependent contractions 
(266,267). Reactive oxygen species cause decrease in NO bioavailability (268) and 
as a positive feedback loop, the formation of hydroperoxides lead to further 
activation of COX (269). Also, since the reactive oxygen species diffuse towards the 
vascular smooth muscle cells, they can stimulate COX in these cells and produce 
more contractile prostanoids. Then the generated PGs directly activate TP receptors 
(270,271). TP receptors are also expressed in endothelial cells and their stimulation 
induces the Rho kinase–dependent inhibition of NO production (272). The isoform α 
of the human TP receptor is negatively and independently regulated either by NO or 
prostacyclin, following the phosphorylation of serine residues by protein kinases G 
and A respectively (273). Also NO can inhibit the activity of thromboxane synthase 
(274), which indicates that a decrease in NO bioavailability may facilitate the TP 
receptor–dependent signalling pathway.  Endothelial dysfunction could also include 
a marked attenuation of the endothelial dependent hyperpolarizing factor (EDHF)-
mediated component of the endothelium-dependent relaxations (247). TP receptor 
stimulation induces a loss in the activity of endothelial small conductance calcium 
activated potassium channels (275), that is an essential component of EDHF-
mediated responses (259). Conversely, the impairment of EDHF-mediated responses 
also can favour the development of endothelium-dependent contractions (276). 
5.1.3  Prostaglandins (PGs)  regulate physiological responses involved in 
diverse functions such as; blood clotting, wound healing, kidney function, blood 
vessel tone, immune response etc.  So, they play more role than just the central role 
in inflammation. PGs are synthesized in a broad range of tissue types and mediate 
via autocrine or paracrine, signal changes within the immediate environment. PGs 
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factor or, the nuclear PPAR receptor (PPARα, PPARγ, PPARδ) (277).  
In the human body PGE2, the most abundant PG, is involved in multiple 
physiological effects including inflammation, regulation of kidney functions and 
blood pressure. Its effect on kidney functions includes regulation of glomerular 
filtration rate, tubular salt and water transports, renin release, renal blood flow and 
vascular tone (278). PGE2 can produce both relaxation and contraction of vascular 
smooth muscle depending on the expression of its four receptor subtypes, namely 
EP1, EP2, EP3 (of which eight splice variants exist in the human) and EP4, which 
are coupled to different signaling pathways (279,  280). Prostacyclin is the other 
major metabolite of arachidonic acid produced by COX and is closely associated 
especially with COX-1 and highly expressed in endothelial cells, (257,281), also 
expressed in vascular smooth muscle cells, neurons, oviducts, intestinal epithelial 
cells and embryonic cells (282). Prostacyclin is the favored IP receptors ligand and 
its effects often, but not always, include activation of adenylyl  cyclase and 
subsequent elevation of intracellular cyclic AMP produces relaxation (283,284). 
Depending on the artery and/or the species, a  hyperpolarization can occur that 
involves the opening of one or more of types of potassium channels. Thus, ATP-
sensitive potassium channels (KATP), large conductance calcium-activated potassium 
channels (BKCa),  inwardly rectifying potassium channels (Kir)  and/or voltage 
activated potassium channels (KV) can be associated with the prostacyclin-induced 
relaxation (247). Thus, in numerous vascular beds, prostanoids can be referred to as 
endothelium-  derived hyperpolarizing substances. Due to most of the available 
inhibitors of cyclooxygenase abolish the production of prostaglandins in vascular 
tissues; any endothelium dependent hyperpolarization observed in the presence of 
one of these inhibitors is unlikely to involve prostacyclin (247). 
5.1.4 Endothelium Derived hyperpolarizing factor (EDHF) and 
vascular function 
EDHF: The endothelium controls vascular tone of the underlying smooth muscle 
cells, not only by releasing nitric oxide (NO) and prostacyclin, but also by other 
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hyperpolarizing factor (EDHF), therefore endothelial hyperpolarization is likely due 
to several factors that are site- and species specific, causing vascular smooth muscle 
hyperpolarization and relaxation. EDHF-mediated responses are characterized by: 
increasing in the intracellular calcium concentration, the opening of calcium-
activated potassium channels of small (SKCa) and intermediate (IKCa) conductance, 
and the hyperpolarization of the endothelial cells (286,287). Such EDHF-mediated 
responses, in most arteries, involve the activation of SKCa  (blocked by apamin, 
scyllatoxin, tubocurarine, or UCL 1684) and/or IKCa (blocked by charybdotoxin, 
TRAM-34 or TRAM-39) (288,289,290), 23,24,26 but not that of BKCa (blocked by 
charybdotoxin and iberiotoxin) (291). Both SKCa and IKCa channels are present in 
freshly isolated endothelial cells from various arteries, the combination of apamin (a 
specific inhibitor of SKCa
+ channels) plus charybdotoxin (a nonselective inhibitor of 
BKCa
+, IKCa
+ channels), and of some voltage-dependent K
+(KV
+) channels, abolish 
EDHF mediate responses (289,292).  
Increasing intracellular free calcium in endothelial cells opens KCa
+ channels and 
allow efflux and accumulation of K
+ into the myoendothelial space which triggers 
several  processes  that  explain  the  EDHF  phenomena;  involving  (і)  synthesis  of 
cytochrome  P450 (CYP450) metabolites, a family of epoxides, (іі) transmission of 
endothelial cell hyperpolarization to the vascular smooth muscle via gap junctions, 
and (ііі) K
+ released from the endothelial cells via KCa
+ channels induces smooth 
muscle hyperpolarization by activating Kir channels and/or Na
+-K
+-ATPase on 
vascular smooth muscle cells (293). 
5.1.5 Cytochrome P450 (CYP450):  
These are membrane-bound, heme-containing terminal oxidases in a multienzyme 
system.  CYP450-dependent EDHF plays a significant role in the regulation of 
coronary arteriolar tone by KCa+ channel activation and smooth muscle 
hyperpolarization (294). Epoxyeicosatrienoic acids (EETs) are arachidonic acid 
derived products of cytochrome P450 (CYP450) epoxygenases (295, 296 ). EETs (in 
particular 11, 12-  and 14, 15-EET) activate several intracellular protein kinases 
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protein kinases 1 and 2 (Erk1/2) and increase the proliferation of various cell types, 
such as vascular smooth muscle cells and endothelial cells (296). The arachidonic 
acid metabolizing CYP450 enzymes with prominent roles in vascular regulation are 
the epoxygenases of the CYP 2 gene family (e.g., CYP 2B, 2C8, 2C9, 2C10, and 2J2 
in humans) which generate a series of region-specific and stereo-specific epoxides 
(5,6-, 8,9-, 11,12-, and 14,15-EETs) (297). 
5.1.6 Gap junctions: 
Gap junctions are formed by the docking of two connexons present in adjacent cells 
leading to the creation of an aqueous central pore permitting the transfer of ions and 
polar molecules that provides an electrical continuity allowing a uniform membrane 
potential among coupled cells (298). These are myoendothelial and heterocellular 
and they couple endothelial cells to other endothelial cells and to smooth muscle 
cells, providing a low-resistance electrical pathway between the cell layers 
(299,300). The number of myo-endothelial gap junctions increases with diminution 
in the size of the artery (301, 299), a phenomenon that parallels the contribution of 
EDHF-mediated responses in endothelium-dependent relaxations to vessel size with 
a greater influence in the resistance than in the conductance vessels (302). Although, 
many questions remain unanswered to date, what flows through myo-endothelial gap 
junction is basically unknown. That a single layer of endothelial cell can drive the 
hyperpolarization of multiple layers of smooth muscle cells suggests the 
involvement of an undefined active membrane process in the conducted 
hyperpolarization (303). Few EDHF-mediated responses are associated with a small 
but significant early and transient endothelium-dependent increase in the cyclic-
AMP content of the smooth muscle cells. Stimulation of a calcium-sensitive adenyl 
cyclase isoform results in an increase in the production of cyclic-AMP with 
subsequent enhancement of gap junctional communication (304,305). 
5.1.7 Potassium (K
+):  
K
+  is another mechanism for achieving hyperpolarization and relaxation of the 
underlying vascular smooth muscle cell linked directly to the hyperpolarization of 
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of potassium ions from the intracellular compartment toward the extracellular space 
(306). A moderate increase in the extracellular (myo-endothelial) K
+ concentration 
(1 to 15 mmol/L) induce hyperpolarization (relaxation) of vascular smooth muscle 
by activating the inwardly rectifying K
+  (Kir) channels and the Na
+/ K
+  pump. 
Endothelium is known as thin monolayer and any efflux of potassium from this 
small cell mass into the lumen of the blood vessel is removed by the flowing blood. 
However, an efflux of potassium in the abluminal direction can lead to accumulation 
of these ions in the small intercellular space between endothelial and smooth muscle 
cells and to reach levels sufficient to activate Kir and the Na
+/ K
+ ATPase on the 
latter. Thus, even if K
+  is not EDHF it could contribute to EDHF-mediated 
responses (213,307). 
In order to further understand the mechanisms the relaxation to acetylcholine was 
recorded in the absence or presence of Nω-Nitro-L-arginine methyl ester (L-NAME), 
indomethacin, diclofenac, BaCl2, apamin+charybdotoxin, and arginine.  
mRNA expression of hypertension associated genes in stromal vascular fractions 
(SVFs) of both depots was assessed  by real time RT-PCR. Paraffin-embedded 
tissues were used for histological studies.  
5.2 Methods 
5.2.1 Myography: 
The general protocol for wire myography described in 3.2 was used. 
To determine whether changes in endothelial NO release contributed to the changes 
in Ach relaxation recorded, vessels were pretreated with L-NAME (100μM) for 30 
minutes before Ach concentration-response curves were constructed. For changes in 
EDHF role, vessels were pretreated with combination of apamine (0.5μM)  and 
charybdotoxin (0.1μM) for 15 minutes before Ach curves were generated. Vessels 
were also exposed to barium chloride (30μM) for 15 minutes to determine whether 
the Kir channels were involved in Ach-induced hyperpolarization. To test for the 
role of prostanoids, vessels were pretreated for 30 minutes with the COX inhibitor 
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the presence of these interventions was calculated as described above.  
 
5.2.2 Hypertension arrays: 
RNA samples were extracted from SC and OM tissues as described in section 2.4.2 
in methods. RNA concentrations were determined using nano-drop. Table 4 
indicates samples concentration and purity as determined by A260/A280 ratio. 
Samples with satisfactory concentrations and good purity were converted into cDNA 
as described in 2.4.3 methods. In order to confirm whether yield and purity were 
suitable to run hypertension expression arrays, B-Actin expression was assayed 
using RT-PCR as described in 2.4.4 methods. Table 4 shows CT corresponding to 
each sample. All samples showed b-actin CT lower than 21 and therefore were used 
for hypertension PCR arrays. Table 5 shows selected RNA samples for hypertension 
expression arrays using RT-PCR Applied biosystems ViiA7 as described in section 
2.4.5 in methods. 
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5.3.1 Table 4: Patient characteristics for mechanisms of endothelial      
dysfunction studies. 
 
Variables  MHO 
(n=5) 
PO 
(n=20) 
P 
MHO  
vs PO 
DO 
(n=4) 
P 
DO vs 
Nondiab 
Age 
(years) 
32 (12)  37 (8.3)  0.28  40 (7)  0.41 
BMI 
(kg/m2) 
43 (2.9)  47 (6.9)  0.27  46 (8.2)  0.87 
SBP 
(mmHg) 
123 (11.50  126 (15.5)  0.62  132 (16.6)  0.46 
DBP 
(mmHg) 
68 (7.45)  73 (11.32)  0.33  79 (12.6)  0.26 
MAP 
(mmHg) 
86.2 (7.3)  82 (30.12)  0.76  96.5 (13.7)  0.33 
Proinsulin 
(miU/ml) 
1.83 (1.1-5.3)  8 (3.1-19)  0.03  14.3 (2.9-13.5)  0.49 
FBG 
(mmol/L) 
5.92 (1.3)  6.22 (1.8)  0.73  12.6 (5.8)  0.19 
Insulin 
(miU/ml) 
7.4 (6.1-7.6)  15.6 (11.1-21.7)  0.006  15.41 (8-15)  0.44 
HOMA  2.1 (1.8-2.5)  4.08 (2.6-6.2)  0.08  9.2 (6.2-9.2)  0.01 
HDL 
(mmol/L) 
0.93 (0.44)  0.93 (0.40)  0.98  0.97 (0.4)  0.88 
LDL 
(mmol/L) 
1.8 (0.98)  2.3 (0.8)  0.19  2.7 (0.74)  0.36 
TG 
(mmol/L) 
0.91 (0.73-1.1)  1.2 (1-1.7)  0.10  1.72 (1.4-1.7)  0.05 
Cholesterol 
(mmol/L) 
3.1 (1.41)  3.8 (1.13)  0.27  4.3 (1.2)  0.38 
IL6  
(pg/ml) 
3.5 (1.14)  6 (1.9)  0.02  3.60 (0.6)  0.24 
Leptin 
(ng/mL) 
60 (26.4)  55.8 (25.8)  0.75  34.06 (13.05)  0.14 
 
Data are shown as mean (SD) or median (interquartiles). * P˂0.05, ** P˂0.01, 
*** P˂0.001. 
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To investigate further the endothelial dysfunction reported in chapter 4, more 
experiments  were carried out to determine changes in the roles of NO, 
prostaglandins/COX and EDHF. The role of the Kir channel was also investigated.   
5.4.1 Effect of eNOS inhibition: 
To test for changes in NO contribution to the Ach responses, curves were generated 
in the presence of the eNOS inhibitor, L-NAME. Following incubation with 100 μM 
L-NAME for 30 minutes, the Ach curves for both SC and OM were shifted to the 
right (P< 0.0001 for SC vessels, Figure 30 A, and p˂ 0.0001 for OM Fig 30 B). The 
Imax values for SC vessels dropped from 87.586± 2.537% to 55.102± 55.102% (P= 
0.0942)  and for OM vessels dropped from 67.566±3.633% to 49.391±6.631% 
(P=0.1071). There were no changes in the sensitivities of both vessels to Ach:  The 
pIC50  values were 7.171±0.240  vs  6.994±0.245  control vs L-Name-treated OM 
vessels and 6.885±0.194 vs 6.732±0.367 for SC vessels.  
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Figure 30A:  Inhibition of Ach relaxation of SC vessels by L-NAME. L-NAME 
caused a rightward shift of the Ach curve (p˂  0.0001), but with no change in 
sensitivity. Data points are Mean ± SEM of n=5-7. 
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Figure 30B:  Inhibition of Ach relaxation of OM vessels by L-NAME. L-NAME 
caused a rightward shift of the Ach curve (p˂  0.0001), but with no change in 
sensitivity. Data points are Mean ± SEM of n=5-7. 
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To test for changes in the contributions of prostaglandins, Ach curves were 
generated in the present of 10 µM indomethacin (COX inhibitor). Surprisingly Ach 
curves were potentiated (shifted to the left) under this condition, particularly in the 
OM vessels (Fig 31 B, P˂0.0001). The shifts in the curves for SC vessels were not 
statistically significant (Fig 31  A).  Imax  values increased from 72.067±7.329  to 
86.630±2.174  in  OM  vessels  (P=0.1608), and from 72.530  ±  9.036 to 
89.765±4.424% in SC vessels (P= 0.2563). Sensitivities of both vessels to Ach were 
not changed by pretreatment with Indomethacin. The pIC50 values before vs after 
Indomethacin were 7.287± 0.964 vs 7.763±0.227 for OM vessels and 7.050±0.051 
vs 6.715±0.069 respectively for SC vessel.  
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Figure  31A:  Effect of Inhibition of COX by Indomethacin  in SC vessels. 
Indomethacin had no significant effect on Ach relaxation of the SC vessels. Data 
points are Mean ± SEM of n=4. 
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Figure  31B:  Effect of Inhibition of COX by Indomethacin  in OM vessels. 
Indomethacin caused a leftward shift in the Ach curve of  the OM vessels (p˂ 
0.0001) -indicating an improvement in Ach relaxation. Data points are Mean ± SEM 
of n=5. 
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EDHF is another mediator of Ach relaxation released from the endothelium. To test 
for any changes in EDHF contributions, Ach  curves were constructed in the 
presence of a combination of 0.5  μM  apamin (SKca  blocker) and 0.1  μM 
charybdotoxin (IKca blocker). Under these conditions, Ach curves for both SC and 
OM were shifted to the right. The curve for SC vessels was shifted to the right (Fig 
32  A;  p˂  0.0001)  with Imax reduced from 84.057±5.214 to 28.213±7.581 
(p=0.0004). The curve for OM vessels was significantly shifted to the right (Fig 32 
B; p< 0.0001) with Imax value reduced from 71.095± 5.881 to 42.797±12.6675. 
Sensitivities of both vessel types to Ach were unchanged by pretreatment with 
apamin and charybdotoxin. The pIC50 values were 6.727±0.382 vs 6.290±0.145 for 
SC and 7.104±0.593 vs 5.294±1.454 for OM before and after EDHF blokade 
respectively.  
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Figure 32A:  Effect of blocking EDHF release in SC vessels: Ach curve was 
significantly shifted to the right by Apamin & Charybdotoxin – blockers of EDHF 
release (p˂ 0.0001). Data points are Mean ± SEM of n=7. 
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Figure 32B:  Effect of blocking EDHF release in OM vessels: Ach curve was 
significantly shifted to the right by Apamin & Charybdotoxin – blockers of EDHF 
release (p˂ 0.0001). Data points are Mean ± SEM of n=6. 
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5.4.4 Effect of Kir channel inhibition:    
Following the observation of a significant EDHF role in the Ach response, tests were 
carried out to determine whether the Kir channel activated by EDHF was involved. 
For this, Ach curves were generated in the presence of 30 µM BaCl2 (a relatively 
selective blocker of this channel). Under this condition, Ach curves were shifted to 
the right in both SC (p=0.0001, Fig 33) and OM (p=0.0001). However, significant 
reduction in Imax was only recorded in OM vessels (from 73.400± 11.9600 % to 
58.934± 27.589 %, p= 0.5752). On the other hand, the sensitivities of the SC vessels 
dropped (pIC50 values 7.233± 0.096 to 6.867± 0.211) in the presence of BaCl2 (p= 
0.0874).   
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Figure 33A:  Effect of blocking KIR in SC vessels. 30 µM BaCl2 (Kir blocker) 
caused a rightward shift of Ach curve (p=0.001 value) but without affecting the 
sensitivity and maximum relaxation to Ach. Data points are Mean ± SEM of n= 4. 
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Figure 33B:  Effect of blocking KIR in OM vessels. 30 µM BaCl2 (Kir blocker) 
caused a rightward shift of Ach curve (p=0.001) with slight change in the maximum 
relaxation to Ach (p=0.085). Data points are Mean ± SEM of n= 5. 
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5.5 Hypertension associated gene arrays 
Comparisons were made between the SVF of the depots, SC and OM, of the MHO 
patients and the PO patients separately. Further comparisons were also made 
between the SC and OM SVF of the MHO compared to the PO. 
In the MHO patients the OM SVF compared to the SC SVF expressed significantly 
greater levels of mRNA for AGT (3.7 [1.6, 5.8], p<0.0005), ARG2 (6.7 [0.0001, 
20.5], p=0.02), CLIC5 (5.5 [0.63, 10.3], p=0.02), EPHX2 (2.0 [1.0, 3.1], p=0.05), 
ITPR1 (2.2 [1.3, 3.1], p=0.01) and PRKG1 (3.0 [0.61, 5.3], p=0.004). 
In the PO patients the OM SVF compared to the SC SVF expressed significantly 
greater levels of mRNA for only CLIC5 (8.4 [0.33, 16.5], p=0.04) and PDE3B (2.5 
[0.32, 4.7], p=0.04). 
In the overall analysis of the PO compared to the MHO only COX 2 mRNA was 
significantly up-regulated (7.2 [3.61, 15.3], p=0.008). 
5.6 Histological analysis 
The results from most of the histology samples were very poor and therefore not 
analyzed further.  
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The data showed that NO and EDHF are the key mediators of Ach endothelium-
dependent relaxation in both OM and SC vessels from obese humans (n=29), with a 
greater role for EDHF. The big surprise in the current data was the absence of a role 
for dilator prostaglandins. COX inhibition resulted in a potentiation instead of a 
reduction in Ach relaxation. This  suggests increased activity of contractile 
prostanoids in these vessels, particularly in the OM vessels where such activities 
appear to largely account for the attenuation in Ach relaxation. That the role of 
EDHF in the SC vessels which showed no apparent endothelial dysfunction was 
greater than in the OM vessels with endothelial dysfunction points to lack of a link 
between EDHF contribution and endothelial dysfunction in these vessels. Thus, the 
suggestion from animal vessel experiments that EDHF role increases in obesity as a 
compensatory response to reduction in NO bioavailability is not the case in these 
human adipose micro vessels.  Moreover, EDHF has been shown in apparently 
healthy humans to play a significant  part  in  the vasodilator mechanism of SC 
vessels. EDHF mediated response involves an increase in endothelial cell calcium 
concentration, the opening of Ca
+2  activated K
+  channels of small (SKca) and 
intermediate (IKca) conductances and the hyperpolarization of the endothelial cells 
leading to transfer of the signals to vascular smooth muscle cells and relaxation 
(289,290).  
The differential response by OM and SC vessels to Ach in the presence of BaCl2, 
suggests greater involvement of kir channel in the OM compared with the SC 
vessels. The EDHF response in SC vessels probably involves another type of K 
channel such as BKCa or Kv channels which are other known candidates for EDHF 
response in blood vessel (289, 292).  
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Chapter 6 
Discussion 
   
  140 6.1 Patients Characteristics:  
Blood vessel functions of patients (n=63) who were undergoing surgery for weight 
loss were studied. Although all the patients were morbidly obese (BMI >40 Kg m-2) 
they were further categorized into 3 groups, MHO (n=13), PO (n=42) and diabetic 
(n=8) based on their metabolic profiles. This represents a prevalence of MHO of 
20.6%, PO of 66.7% and T2DM of 12.7% in this study cohort. As these were not 
samples collected from consecutive patients unintended selection bias may be likely. 
Therefore any observation on the prevalence of the different phenotypes in a 
morbidly obese population only refers to this cohort. The prevalence of MHO and 
PO in this cohort appears comparable to those reported by other groups from 10 and 
40%  (195), however, the prevalence of T2DM  in this study population seem 
significantly lower than those reported, which range from 22-50% 
(308,309,310,311). As the overall prevalence of T2DM in the Qatari general 
population is currently 16.7% this figure of 12.7 % in our morbidly obese cohort 
may just reflect selection bias (312,313). 
The metabolic profiling was based on the  patient’s plasma insulin level, insulin 
sensitivity, plasma glucose and blood pressures. There were no noticeable 
differences in lipid profiles between these groups. These results suggest that 
although obesity does not necessarily translate into insulin resistance and increased 
risk of metabolic comorbidities (314) in all subjects, as demonstrated by the small 
group of MHOs, most patients studied were at risk of future health complications. 
 
6.2 Vascular reactivity: 
The impact of obesity on blood vessels accounts for much of the morbidity of the 
condition. The endothelium is usually among the first targets of the changing milieu 
with the potential to change both vasodilator and vasoconstrictor mechanisms. Due 
to technical difficulties in the direct measurement of vascular reactivity in humans, 
most studies have relied on indirect assessment of vascular functions in obese 
individuals such as the forearm flow mediated dilatation technique (315,316) with 
variable results. This current study is one of the few that have used wire myography 
  141 to directly measure reactivity of OM and SC vessels from obese individuals to 
provide a clearer picture of the impact of surrounding fat on microvascular function.  
6.2.1 Response to vasoconstrictors: 
Two vasocontractile mechanisms were tested in this study – depolarization-induced 
with KCl and adrenergic receptor activation with noradrenaline. Maximum 
contractions in response to depolarization were greater in the OM compared to SC 
vessels. This was particularly so with the pathologically obese group and probably 
reflects differences in the impact of the local adipose environment on the contractile 
mechanisms of these microvessels. The lack of any measurable difference in the 
responses of SC vessels from the 3 metabolic groups to KCl suggests a comparable 
SC profile for the groups. KCl acts by depolarizing vascular  smooth muscle 
membrane leading to opening of voltage sensitive Ca
2+ channels which allow for 
Ca
2+ influx and activation of contractile proteins. Since maximum contractions are 
functions of cytosolic calcium and the contractile proteins, the results suggests 
greater mobilization of calcium and/or contractile proteins in the OM compared to 
SC. Differences in the amount of contractile proteins is less likely to explain the KCl 
data since the force generated by each vessel segment was normalized to size. More 
so, the mRNA expression arrays show no significant difference in the expression of 
α actin between the two vessel types. Although the sensitivities of the 3 OM vessel 
groups to KCl were not statistically different, differences in their sensitivities to 
cytosolic calcium (Ca
2+ sensitization) cannot be ruled out. Variation in local release 
of adipokines can indeed affect the later (156, 157).  
In contrast to depolarization-induced contractions, there were no differences in both 
maximum contractions induced by and sensitivity to adrenergic receptor activation 
in OM vessels from the 3 metabolic groups. The picture was however different for 
the SC vessels, which showed greater sensitivity for PO and DO vessels compared to 
MHO vessels to noradrenaline. The reasons for these differences in noradrenergic 
sensitivities are not clear but may relate to impact of the local adipose tissue on 
adrenergic  receptor  activity.  NA  contraction  involves  activation  of  α-adrenergic 
receptors which are coupled to both Ca
+  influx and generation of inositol 
triphosphate (IP3) which signals intracellular Ca
+  release from sarcoplasmic 
  142 reticulum. Simultaneous activation of β adrenoceptor (which is rare on the vascular 
smooth muscle (317)  would  theoretically  dampen  the  effect  of  α  adrenergic 
activation. Over activity of the sympathetic nervous system in obesity may lead to 
increased sympathetic outflow which may elevate BP (224), and insulin secretion 
(225). Egan et al, demonstrated that overweight subjects, most of them hypertensive, 
exhibit  increased  α-adrenergic vascular tone (318). Due to reduction of skeletal 
muscle blood flow in hypertension resulting from neural vasoconstriction could be 
the primary cause of the insulin resistance and the attendant hyperinsulinemia (226), 
as well as sympathetic nervous activation can directly contribute to the lipid change 
which is part of the metabolic syndrome (227).Chronic metabolic diseases including 
type 2 diabetes and metabolic syndrome are widespread in those with obstructive 
sleep apnoea (OSA). Furthermore, obesity is the main risk factor and a common 
characteristic of OSA (319).  The latter may worsen the effect of obesity on 
cardiometabolic risk, through mechanisms which it may trigger several pathological 
mediating pathways including; sympathetic activation, neurohumoral changes, 
glucose homeostasis disruption, inflammation and oxidative stress via chronic 
intermittent hypoxia (CIH), and these may ultimately cause deterioration in the 
metabolic function (320). South Asians have a higher prevalence of type 2 diabetes, 
dyslipidemia, and CVD, and it is possible that South Asians are at greater risk of 
OSA than white Europeans (319).  
6.2.2 Response to vasodilators: 
The current data reveal both depot-specific and metabolic impact of obesity on 
endothelium-dependent micro vascular dilator mechanisms in humans. The OM 
vessels from PO and DO groups were particularly affected, suggesting a local 
impact that is exaggerated by the metabolic status of the individuals. Thus, OM 
depot is more heavily implicated in metabolic syndrome and more extensively 
infiltrated with immune-inflammatory cells, such as macrophages and T-
lymphocytes (86), whereas, the subcutaneous depot  appears less metabolically 
active, secrete more leptin and less free fatty acids (79). The depot specificity of the 
endothelial dysfunction is consistent with previous report (86) and attributable to the 
more pathogenic changes reported for OM compared with the SC depot (86). 
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involvement (27 %) in Ach relaxation of these vessels, albeit reduced by about 10 % 
compared with SC vessels. Reactivity in the previous report referred was measured 
by imaging, and so, the difference in technique might be a factor in the difference in 
NO involvement in OM vessel relaxation reported. Differences in the pathogenicity 
of the OM depot of the two obese populations (Caucasian vs Qatari) might also 
explain the differences observed. Typically Ach vasodilatation is attributed to NO 
release from the endothelium (116), although additional mediators are known to be 
involved in the small vessels (117). NO relaxes blood vessels by activating soluble 
Gauanylyl cyclase (sGC) in the VSMC leading to the generation of cyclic guanine 
monophosphate (cGMP) and the activation of protein kinase G (PKG) which among 
other things will activate K+ channels leading to relaxation (241, 292).  
Since NO alone could not fully account for Ach relaxation of these vessels, the role 
of 2 other known endothelium-dependent dilator mechanisms (EDHF and 
prostanoids) were explored. In small vessels, the contribution of EDHF becomes 
more apparent when endothelium-dependent vasodilation persists in the face of 
inhibition of NOS (292,321). EDHF accounted for 44% of maximum relaxation to 
Ach in the OM vessels and 64 % in the SC vessels. This suggests even a greater 
contribution by EDHF to endothelium-dependent dilatation of these vessels 
compared with NO. Since EDHF played a bigger role in the SC compared with OM 
vessels, its contribution could not be linked to endothelial dysfunction in these 
vessels. Therefore the current data shows that the widely held suggestion (based on 
animal vessels) that EDHF may act as a back-up vasodilator system  when NO 
production or bioavailability is impaired (294,322,323,324) is not the case in human 
adipose microvessel. Moreover, similarly large EDHF contribution to dilatation of 
SC vessels from apparently healthy humans has been reported (293). However, it 
could not be determined if EDHF contribution to OM vessel dilatation was altered in 
this study as there is no normal reference, although this could not be ruled out. 
Interestingly the EDHF responses in SC and OM vessels appear to activate different 
K channel mechanisms to hyperpolarize the vascular smooth muscle. Whereas, Kir 
was demonstrably involved in OM response, it was not as clear in the SC vessel 
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involved in EDHF response include BKCa and KV (325) The EDHF response in SC 
vessels probably involves another type of K channel such as BKCa or Kv channels 
which are other known candidates for EDHF response in blood vessel). The term 
endothelium-derived hyperpolarizing factor (EDHF) was coined (247) for molecule 
(s) of yet unknown identity, released by the endothelium which then hyperpolarizes 
the underlying vascular smooth muscle to produce vasodilatation. A number of 
candidates have been reported as EDHF in different vascular beds, including K
+, 
H2S, EET, CytP450, PGI2, and even NO (325 ). The EDHF candidate (s) released 
by the adipose micro vessels in this study are not known but EDHF-mediated 
hyperpolarization of human vessels has been shown to involve the release of K
+ 
from endothelial cells, and the subsequent activation of Kir or Na-K-ATPase leading 
to relaxation (326). Even though the candidates in this study were not identified, 
they share the characteristic of requiring the activation of both SKCa  and IKCa 
channels of endothelial cells prior to their transfer to vascular smooth muscle cells. 
Hence, the responses were sensitivity to the combination of  charybdotoxin and 
apamin (327) which inhibit IKCa and SKCa respectively and typically used to block 
EDHF response. Overall, the data show that NO and to a greater extend EDHF, are 
involved in endothelium-dependent dilatation of both OM and SC vessels from 
obese individuals. While NO and EDHF could fully account for Ach relaxation of 
SC vessels, this is not the case with OM vessels that clearly show endothelial 
dysfunction. Since prostanoids such as prostacyclin (PGI2) and PGE2 could mediate 
endothelium-dependent dilatation, the role of COX pathway was explored to see 
whether that would explain the residual Ach relaxation recorded. COX inhibition 
with indomethacin resulted in an enhancement instead of a reduction in Ach 
relaxation. This was particularly profound in OM vessels where hitherto the 
response to Ach was attenuated. The data following COX inhibition suggested that 
increased contractile prostanoid activity was largely responsible for the attenuation 
in Ach relaxation of these vessels. This is consistent with recent report which 
suggested that endothelial dysfunction in visceral fat is driven in part via increased 
activity of the eicosanoid/cyclooxygenase pathway in human obesity. As with 
  145 current data, COX inhibition did not change Ach response in the SC vessels where 
vasodilator function was relatively preserved. COX products have also been shown 
to impair NO vascular activity in other human diseases such as hypertension (328) 
and chronic renal failure (329). Although the COX isoform responsible for 
heightened contractile prostanoid activity in this study was not determine, COX1 
was suggested in previous human studies (184). Both COX1 and COX2 isoforms 
have been implicated in mechanisms of endothelial dysfunction via generation of 
vasoconstrictor prostanoids in animal models with isoform specificity relating to 
disease phenotype (325,327,330).    In diabetes, due to increased synthesis of 
vasoconstrictor prostanoids and endothelin (161). Endothelin-1 activates endothelin 
A receptors on VSMC to enhance vasoconstriction. Diabetes also induces PKC 
activity, NF-κβ  production,  and  generation  of  oxygen-derived free radicals in 
VSMC, similar to these effects in endothelial cells (165).  However, dysregulation of 
vascular smooth muscle function is exacerbated by impairments in sympathetic 
nervous system function (166). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  146 6.3 Conclusion 
The data so far show clear differences between OM and SC vessels obtained from 
morbidly  obese Qataris in respect of endothelium-dependent relaxation and 
noradrenergic sensitivity, with more marked alteration in the vascular mechanisms 
in the OM compared with SC. The results also show altered noradrenergic 
(density/function) sensitivity and attenuated endothelium-dependent relaxation 
compared to SC arterioles and abnormal endothelial function appears to be due to 
decreased NO bioavailability, which may underlie these depot specific responses. 
The latter appears to be at least in part due to increase in COX antagonistic activity.  
6.4 Limitation of the study: 
i.  The major limitation, perhaps due to cultural reasons, was that it took longer to 
recruit patients into the various studies as many were unwilling to provide signed 
consent for participation in any research. 
ii.  It was difficult to determine how much the various surgical procedures would have 
impacted on the responsiveness of the tested vessels as the numbers were too small 
to carry out such comparisons, and   
iii.  Due to small number of diabetic patients some of the data skewed. 
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Figure  34:  Proposed mechanisms of endothelium-dependent relaxation of 
adipose tissue micro vessels. Activation of the endothelial cell by a dilator agonist 
such as Ach, leads to release of NO or EDHF which is transferred to the underlying 
smooth muscle cell to cause its relaxation. NO activates soluble guanylyl cyclase 
which generates cGMP which in turn activate PKG leading to relaxation of the 
vascular smooth muscle cell. On its side, EDHF activates K channels  (e.g Kir) 
causing efflux of K+ and hyperpolarization of the smooth muscle cell. 
Hyperpolarization of the smooth muscle cell leads to closure of voltage sensitive 
Ca
2+ channels on its membrane and leading to relaxation. The current data suggests 
that COX activity is increased in the favour of contractile prostanoids which appear 
to work against these dilator mechanisms particularly the NO mechanism thereby 
contributing to the endothelial dysfunction recorded. Drugs used to study these 
pathways and their sites of actions are indicated in red.  
 
 
 
 
  148 6.5 Future studies 
•  Continue the study for endothelium dependent relaxation especially for 
EDHF mechanisms between vessels from the 2 depots and the groups of 
patients. 
•  To assess changes in the involvement of ion channels for K+, Ca+ channels. 
 
•  Reprocess the embedded paraffin block for histology to look the differences 
between the MHO and PO patients. 
•  Assessment of changes in proteins related to vascular functions by western 
blot.  
 
•  Confirming hypertension gene array results by checking the validity for 
single PCR.  
 
 
6.5.1 Immunohistochemical analysis. 
6.5.1 .1Estimation of adipocyte number, size and capillary density 
Paraffin processing was performed by the Histology Department at HMC., Doha, 
Qatar. Briefly 0.3g tissue from each depot was fixed in 10% formalin for 24h at 
room temperature and then transferred to 50% ethanol at +4
oC prior to being 
embedded  in  paraffin.  3  μm  sections  were  deparaffinized  and  dehydrated  by 
incubation in Xylene (Sigma-Aldrich, UK) for 20 min followed by incubation with 
100, 90, 80, 70, and 60% ethanol for about 2 min for each step.  
Lectin staining (Mahrokh Nahadani, UCL, UK) was used as a marker of capillaries. 
Slides were rinsed with 0.1M sodium phosphate buffer (PBS, pH 7.4) for 20 min. 
The sections were incubated for 30 min in a dark moist container with the staining 
solution containing lectin-fluorescein isothiocyanate (FITC)-GS conjugate (from 
Griffonia simplicifolia; Sigma-Aldrich), 25 μg/ml,  lectin tetramethylrhodamine 
isothiocyanate conjugate (TRITC)-UEA conjugate [from Ulex europaeus (UEA), 
Sigma-Aldrich],  10μg/ml,  and  4’,  6-diamidino-2-phenylindole, dihydrochloride 
(DAPI) 0.3μg/ml (Sigma-Aldrich, UK). The GS-lectin stains the endothelium and 
generally used as a marker of capillary; UEA stains the capillaries and DAPI stains 
  149 the nuclei. The sections were rinsed with PBS (40 min) and then mounted on 
microscope slides with water-soluble mounting medium (Cardinal Health, Dublin).  
Images of the stained sections were captured with a Zeiss Axioplan 2 upright 
microscope (Intelligent Imaging Innovations, Denver, USA) using a Photometrics 
CoolSnap HQ CCD camera and a Sutter Lambda LS 175W Xenon arc lamp. A 
planar Apochromat 20x/0.75 objective lens, three filters sets (DAPI-EX 360/40, 
FITC-EX HQ487/25, and CY3-EX HQ535/50) and Slidebook Software version 2.0 
were used for image capture. 
Samples were processed and embedded at histology department in HMC. Images were 
stained and captured as shown in the figure 35.  
 
 
 
 
Figure 35:  A typical example of the various stained sections of SC and OM 
adipose tissue shows poorly stained adipocytes. 
 
H & E stain for SC & OM 
EVG stain for SC & OM 
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